

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**THE FIRST AND FINAL APPLICATION OF SSG ADVISORS, LLC, INVESTMENT BANKERS FOR THE DEBTORS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD APRIL 1, 2024 THROUGH AND INCLUDING SEPTEMBER 5, 2024**

If you object to the relief requested, you must respond in writing. Unless otherwise directed by the Court, you must file your response electronically at <https://ecf.txnb.uscourts.gov> no more than twenty-four (24) days after the date this motion was filed. If you do not have electronic filing privileges, you must file a written objection that is actually received by the clerk and filed on the docket no more than twenty-four (24) days after the date this motion was filed. Otherwise, the Court may treat the pleading as unopposed and grant the relief requested.

A hearing will be conducted on the matters set forth in this motion on October 24, 2024 at 9:30 a.m. (prevailing Central Time) in Courtroom #1, 14th Floor, Earle Cabell Federal Building, 1100 Commerce Street, Suite 1254, Dallas, Texas 75242.

You may participate in the hearing either in person or by an audio and video connection. Audio communication will be by use of the Court's dial-in facility. You may access the facility at 650.479.3207. Video communication will be by the use of the Cisco WebEx platform. Connect via the Cisco WebEx application or click the link on Judge Jernigan's home page. The meeting code is 2304-154-2638. Click the settings icon in the upper right corner and enter your name under the personal information setting. WebEx hearing instructions may be obtained from Judge Jernigan's hearing/calendar site: <https://www.txnb.uscourts.gov/judges-info/hearing-dates/chief-judge-jernigans-hearing-dates>.

Hearing appearances must be made electronically in advance of electronic hearings. To make your appearance, click the "Electronic Appearance" link on Judge Jernigan's home page. Select the case name, complete the required fields and click "Submit" to complete your appearance.

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Avenue, Dallas, Texas 75201.



**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:  EIGER BIOPHARMACEUTICALS, INC., <i>et al.</i> <sup>1</sup>  Debtors.	Chapter 11  Case No. 24-80040 (SGJ)  (Jointly Administered)
--	---

**SUMMARY COVER SHEET TO THE FIRST AND FINAL APPLICATION OF SSG  
ADVISORS, LLC, INVESTMENT BANKERS FOR THE DEBTORS,  
FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF  
EXPENSES FOR THE PERIOD APRIL 1, 2024 THROUGH AND INCLUDING  
SEPTEMBER 5, 2024**

Name of Applicant	SSG Advisors, LLC
Authorized to Provide Professional Services as:	Investment Bankers for the Debtors
Date of Retention:	<i>Nunc Pro Tunc</i> to April 1, 2024
Petition Date:	April 1, 2024
Period for which compensation and reimbursement is sought:	April 1, 2024 through September 5, 2024
Amount of Compensation sought as actual, reasonable and necessary:	\$2,718,000.00
Amount of Expense Reimbursement sought as actual, reasonable and necessary:	\$9,387.99
<b>Total Fees and Expenses Requested:</b>	<b>\$2,727,387.99</b>
Amount Paid:	\$2,727,387.99

This is a(n): \_\_\_ monthly \_\_\_ interim X final application.

**This is SSG Advisors, LLC's First and Final Fee Application in these cases.**

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Avenue, Dallas, Texas 75201.

<b>Period Covered</b>	<b>Fees</b>	<b>Expenses</b>	<b>Total</b>
Monthly Fee 5/1/2024 - 5/31/2024	\$50,000.00	\$5,030.67	<b>\$55,030.67</b>
Transaction Fee (Zokinvy Assets) 5/4/2024	\$1,329,000.00	\$0.00	<b>\$1,329,000.00</b>
Monthly Fee 6/1/2024 - 6/30/2024	\$50,000.00	\$0.00	<b>\$50,000.00</b>
Monthly Fee 7/1/2024 - 7/31/2024	\$50,000.00	\$2,435.83	<b>\$52,435.83</b>
Transaction Fee (Avexitide Assets) 7/10/2024	\$1,053,000.00	\$0.00	<b>\$1,053,000.00</b>
Monthly Fee 8/1/2024 - 8/31/2024	\$50,000.00	\$1,921.49	<b>\$51,921.49</b>
Transaction Fee (Lonafarnib & Lambda Assets) 8/3/2024	\$186,000.00	\$0.00	<b>\$186,000.00</b>
*Less 50% of Monthly Fees Paid Beginning July 1, 2024	(\$50,000.00)	\$0.00	<b>(\$50,000.00)</b>
<b>TOTAL:</b>	<b>\$2,718,000.00</b>	<b>\$9,387.99</b>	<b>\$2,727,387.99</b>

*\*Per the Engagement Agreement, Transaction Fees are to be reduced by 50% of monthly fees paid beginning July 1, 2024.*

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**FIRST AND FINAL APPLICATION OF SSG ADVISORS, LLC, INVESTMENT BANKERS FOR THE DEBTORS, FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD APRIL 1, 2024 THROUGH AND INCLUDING SEPTEMBER 5, 2024**

SSG Advisors, LLC (“SSG” or “Applicant”), Investment Bankers for the Debtors, hereby submits this *First and Final Fee Application of SSG Advisors, LLC, Investment Bankers for the Debtors, for Allowance of Compensation for Services Rendered and Reimbursement of Expenses for the Period April 1, 2024 Through and Including September 5, 2024* (this “Application”), pursuant to sections 327 and 328 of title 11 of the United States Code (the “Bankruptcy Code”), Rules 2014(a) and 2016 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), Rules 2014-1 and 2016-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the Northern District of Texas, Dallas Division (the “Local Rules”) and this Court’s May 13, 2024 *Order authorizing the employment and retention of SSG Advisors, LLC as Investment Bankers for the Debtors as of the Petition Date* [Doc. 258] (the “Retention Order”). By this Fee Application, SSG, investment bankers for the Debtors in the above-captioned Chapter 11 Cases (the “Chapter 11 Cases”), hereby applies to the Court for the allowance of

---

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Avenue, Dallas, Texas 75201.

compensation for services rendered in the amount of \$2,727,387.99. The requested compensation consists of monthly fees totaling \$200,000.00 for the period commencing April 1, 2024 through and including September 5, 2024 (the “Application Period”) plus Transaction Fees of \$2,518,000.00 plus the reimbursement of expenses totaling \$9,387.99, with respect to its services as investment bankers for the Debtors. In support of this Application, SSG represents as follows:

### **JURISDICTION AND VENUE**

1. The United States Bankruptcy Court for the Northern District of Texas (the “Court”) has jurisdiction over this matter pursuant to 28 U.S.C. § 1334. This matter is a core proceeding pursuant to 28 U.S.C. § 157(b). The Debtors confirm their consent, pursuant to rule 7008 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), to the Court’s entry of a final order in connection with this motion.

2. Venue is proper before this Court pursuant to 28 U.S.C. §§ 1408 and 1409.

3. The bases for the relief requested herein are sections 327(a), 328(a), and 1107(b) of title 11 of the United States Code (the “Bankruptcy Code”), Bankruptcy Rules 2014(a) and 2016, Rules 2014-1 and 2016-1 of the Bankruptcy Local Rules for the Northern District of Texas (the “Local Rules”), and the Procedures for Complex Chapter 11 Cases in the Northern District of Texas.

### **BACKGROUND**

#### **A. The Bankruptcy Case**

4. On April 1, 2024 (the “Petition Date”), each of the Debtors filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code. The Debtors are operating their business and managing their property as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. These chapter 11 cases have been consolidated for procedural purposes only

and are being administered jointly. No party has requested the appointment of a trustee or examiner in these cases, and no statutory committee has been appointed.

5. A detailed description of the Debtors and their businesses, including the facts and circumstances giving rise to the Debtors' Chapter 11 Cases, is set forth in the *Declaration of David Apelian in Support of the Chapter 11 Petitions and First Day Pleadings* (the "First Day Declaration") [Doc. 19].

**B. Retention of SSG**

6. To solicit competing offers to the proposed stalking horse bid (the "Zokinvy Stalking Horse Bid") by Sentyln Therapeutics, Inc ("Sentyln") for the Zokinvy assets (the "Zokinvy Assets") and concurrently run a marketing process for the remaining pipeline assets of Eiger (Avexitide, Lonafarnib and Lamba program assets, collectively "the Remaining Assets") on a separate timeline (the "Sale"), the Debtors elected to retain SSG to provide investment banking services based on SSG's substantial expertise in advising troubled companies, including multiple life science companies, in connection with capital raising and asset sales.

7. Accordingly, On April 23, 2024, the Debtors filed the *Debtors' Application for Entry of an Order Authorizing the Employment and Retention of SSG Advisors, LLC as Investment Bankers for the Debtors as of the Petition Date* [Doc. 156] (the "SSG Retention Application") seeking to retain SSG as investment banker to the Debtors pursuant to the terms of the Engagement Letter dated March 22, 2024 (the "Engagement Agreement"). A true and correct copy of the Engagement Agreement is attached hereto and made a part hereof as **Exhibit A**.

8. On May 13, 2024, the Court entered the *Order authorizing the employment and retention of SSG Advisors, LLC as Investment Bankers for the Debtors as of the Petition Date* [Doc. 258] (the "Retention Order"), which sets forth the procedure for final compensation and

reimbursement of expenses to SSG in these Chapter 11 Cases pursuant to the terms of the Engagement Agreement. A copy of the Retention Order is attached hereto as **Exhibit B**.

9. As set forth in the Retention Application, the Debtors engaged SSG on March 22, 2024 to serve as its investment banker in connection with a sale of its assets.

10. SSG worked with the Debtors, its counsel and financial advisors to evaluate potential buyers. In this regard, SSG conducted due diligence, prepared a teaser, populated a data room and completed a confidential information memorandum, which described the Debtors' assets, operations and financial history.

### **C. Sale Process**

11. Immediately following the execution of the Engagement Agreement dated March 22, 2024, SSG worked with the Debtors to quickly engage and evaluate potential buyers, including prospective strategic (related businesses) and financial (private equity firms interested in adding the Debtor to their existing investment portfolios) partners, for all of the Debtors' assets

12. Prior to the petition date, SSG solicited competing offers to the Zokinvy Stalking Horse Bid and concurrently began a marketing process for the Remaining Assets.

13. In addition to developing the list of potentially interested parties, SSG also conducted its own independent due diligence regarding the Debtors. This independent due diligence included, but was not limited to, the following: a review of the Debtors' drug pipeline, financials and operations, calls with management and an analysis of the Debtors' marketplace.

14. SSG worked closely with the Debtors' management team to draft the appropriate marketing materials, including "Teasers," which are one-page documents to be distributed to potential buyers, summarizing the investment opportunity and key company highlights.

15. SSG also developed a Confidential Information Memorandum ("CIM") for the Debtors, which provided a detailed descriptions of the Debtors' business, assets and historical performance, including, but not limited to, an overview of the Debtors' commercialized drug and drug candidates in development, operating performance, capital structure, go-forward strategy and investment highlights to be distributed to interested parties only after that party executed a non-disclosure agreement ("NDA").

16. SSG also worked closely with the Debtors to build a comprehensive virtual data room. The virtual data room prepared and maintained by SSG and the Debtor provided information regarding all aspects of the Debtors' business, including, but not limited to: (1) Detail on the Debtors' commercialized drug and drug candidates in development, (2) business operations, (3) human resources and benefits, (4) accounting, (5) finance, (6) intellectual property, and (7) legal.

17. While SSG had conversations with potential buyers both prepetition and immediately after the Petition Date, the broader marketing process commenced on April 4, 2024. SSG contacted and distributed a teaser to 342 parties, including 241 potential strategic buyers and 101 potential financial buyers, to solicit interest in a sale transaction involving the Debtors' assets. Relevant information regarding the Debtors' business was made available in a data room, allowing potential bidders to conduct further diligence on the Debtors' business, subject to the execution of an appropriate NDA. During the marketing period, SSG negotiated non-disclosure agreements, held calls and meetings with prospective investors, coordinated and participated in management meetings and discussions, facilitated interested parties' due diligence and solicited offers.

18. On April 1, 2024, the Debtors filed the *Debtors' Motion for Entry of an Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentyln Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid*



*Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), if Any; (D) Establishing Bid Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; and (III) Granting Related Relief [Doc. 13].* Subsequently, on April 5, 2024 the Court entered the *Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentynl Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), if Any; (D) Establishing Bid Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; and (III) Granting Related Relief (the “Bid Procedures Order”)* [Doc. 94]. This order approved Sentynl Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser (the “Zokinvy Stalking Horse Purchaser”) at a purchase price of \$30,000,000.00, which SSG helped negotiate up from a pre-petition offer of \$14,000,000.

19. On April 15, 2024, the Debtors filed the Notice of Filing of Revised Bidding Procedures [Doc. 119], which included the revised bidding procedures (the “Bid Procedures”)

20. On the Zokinvy Assets bid deadline of April 15, 2024, one additional qualified bid was received in addition to the bid from the Zokinvy Stalking Horse Purchaser.

21. In accordance with the Bid Procedures, on April 17, 2024, the Debtors conducted an auction (the “Auction”) for the sale of the Zokinvy Assets. After 35 rounds of bidding, as set

forth in the *Notice of Successful Bidder* [Doc. 133], the Debtors selected the Stalking Horse Purchaser as the winning bidder with a purchase price of \$46,100,000.00 (the “Zokinvy Successful Bid”) and Eton Pharmaceuticals, Inc. as the Backup Bidder with a bid of \$46,000,000.00 (the “Zokinvy Backup Bid”).

22. On April 24, 2024, the Court entered the *Order (I) Approving the Sale of the Debtors’ Zokinvy Assets, (II) Authorizing Assumption and Assignment of Certain Executory Contracts and Unexpired Leases Related Thereto, and (III) Granting Related Relief* [Doc. 162] (the “Zokinvy Sale Order”), which approved the sale to Sentynl Therapeutics, Inc. The sale of the Zokinvy Assets to Sentynl Therapeutics, Inc. closed on May 4, 2024.

23. Upon effectuating the sale of the Zokinvy Assets, SSG immediately began negotiations with multiple parties on the Remaining Assets.

24. On June 12, 2024, the Debtors filed the *Revised Notice of Sale, Bid Procedures, Auction, and Sale Hearing* [Doc. 331], which included revised dates and deadlines for the Bid Deadline, Auction, and Sale Hearing for the Remaining Sale Transaction(s) (the “Revised Bid Procedures”).

25. Following several weeks of additional marketing on the Remaining Assets, the Debtors, in consultation with their advisors, made the decision to enter into a stalking horse purchase agreement (the “Avexitide Stalking Horse APA”) for \$10,000,000 with Spruce Bioscience, Inc. (the “Avexitide Stalking Horse Purchaser”) for the Avexitide assets as set forth in the Notice of Selection of Stalking Horse Bidder [Doc. 333].

26. Throughout the process, SSG continued to interface with potential bidders for the Avexitide assets to solicit higher or otherwise better proposals from third parties. The Debtors secured, in addition to the Avexitide Stalking Horse APA, one additional Qualified Bid.

27. In accordance with the Revised Bid Procedures, on June 17, 2024, the Debtors conducted an auction via Zoom for the sale of the Avexitide Assets with 122 rounds of bidding over three (3) hours. Following the conclusion of the Avexitide Auction, as set forth in the *Notice of Selection of Winning Bid* [Doc. 350], the Debtors selected Amylyx Pharmaceuticals, Inc. (the “Avexitide Purchaser”) as the Winning Bidder with a Purchase Price of \$35,100,000 plus the aggregate amount of Determined Cure Costs and Assumed Liabilities (the “Avexitide Winning Bid”) with Spruce Bioscience, Inc. as the Back-Up Bidder at \$35,000,000 plus the aggregate amount of Determined Cure Costs and Assumed Liabilities.

28. On June 27, 2024, the Court entered the *Order (I) Approving the Sale of the Debtors’ Avexitide Assets, (II) Authorizing Assumption and Assignment of Certain Executory Contracts and Unexpired Leases Related Thereto, and (III) Granting Related Relief* [Doc. 376] (the “Avexitide Sale Order”), which approved the sale to Amylyx Pharmaceuticals, Inc. The sale of the Avexitide Assets to Amylyx Pharmaceuticals, Inc. closed on July 10, 2024.

29. Immediately following the successful sale the of Avexitide assets, SSG initiated a targeted remarketing of the Lonafarnib and Lambda assets.

30. On July 13, 2024, Debtors filed the *Further Revised Notice of Bid Deadlines* [Doc. 422], which included revised dates and deadlines related to the Bid Deadline for the Lonafarnib sale transaction (the “Lonafarnib Sale Transaction”) and the Lambda sale transaction (the “Lambda Sale Transaction” and together with the Lonafarnib Sale Transaction, the “Lonafarnib/Lambda Sale Transactions”).

31. In accordance with the Bid Procedures, the Debtors set the deadline to submit Qualified Bids for the Lonafarnib Sale Transaction for July 19, 2024. After discussions with their advisors, the Debtors elected to pursue a private sale transaction with Eiger InnoTherapeutics, Inc.

(the “Lonafarnib/Lambda Purchaser”) for the purchase of the Lonafarnib Assets, which culminated in the execution of the Lonafarnib APA.

32. The Debtors cancelled the auction for the Lonafarnib Assets and designated the Lonafarnib/Lambda Purchaser as the highest and best bid for the Lonafarnib Assets, as set forth in the *Notice of Cancellation of Auction(s), Designation of Winning Bid for the Lonafarnib Sale Transaction, and Transition to Private Sale Process for Lonafarnib/Lambda Sale Transactions* [Docket No. 489] (the “Lonafarnib/Lambda Sale Notice”). The Debtors selected the Lonafarnib/Lambda Purchaser as the winning bidder for the Lonafarnib Assets with a Base Purchase Price of \$5,200,000 plus (a) if Purchaser does not assume any Cross-Over Contract, then up to \$180,000 in the aggregate, (b) if Purchaser assumes the IQVIA Contracts, then up to \$2,180,000, (c) if Purchaser assumes the Biorasi Contracts and the IQVIA Contracts, then up to \$2,380,000, or (d) if Purchaser assumes the Biorasi Contracts but not the IQVIA Contracts, then up to \$380,000 in the aggregate (the “Winning Lonafarnib Bid”).

33. In accordance with the Bid Procedures, the Debtors set the deadline to submit Qualified Bids for the Lambda Sale Transaction for August 2, 2024, which was subsequently extended to August 16, 2024 (the “Lambda Bid Deadline” and together with the Lonafarnib Bid Deadline, the “Lonafarnib/Lambda Bid Deadlines”). After ongoing negotiations with the Lonafarnib/Lambda Purchaser, the Debtors determined a sale of the Lambda Assets, in addition to the Lonafarnib Assets, to the Lonafarnib/Lambda Purchaser was in the best interest of the estate. The Debtors elected to transition to a private sale transaction with the Lonafarnib/Lambda Purchaser for the purchase of the Lambda Assets, which culminated in the execution of the Lambda APA.

34. The Debtors cancelled the auction for the Lambda Assets and designated the Lonafarnib/Lambda Purchaser as the highest and best bid, as set forth in the Private Sale Notice. The Debtors selected the Lonafarnib/Lambda Purchaser as the winning bidder with a Base Purchase Price of \$1,000,000 plus up to \$269,000 in the aggregate in Cure Costs (the “Winning Lambda Bid”)

35. On August 2, 2024, Debtors filed the *Notice of Cancellation of Auction(s), Designation of Winning Bid for the Lonafarnib Sale Transaction, and Transition To Private Sale Process for Lonafarnib/Lambda Sale Transactions* [Docket No. 489] (the “Lonafarnib/Lambda Sale Notice”) selecting Eiger InnoTherapeutics, Inc. as the highest and best bidder for the Lonafarnib/Lambda Assets, and served the Lonafarnib Assigned Contracts and Cure Amounts and the Lambda Assigned Contracts and Cure Amounts (the “Assignment Notice”).

36. On August 5, 2024, Debtors filed the *Debtors’ Emergency Motion for the Entry of an Order (I) Authorizing the Sale of the Lonafarnib and Lambda Assets Free and Clear of Liens, Claims, Encumbrances, and Other Interests, (II) Authorizing the Assumption and Assignment of Executory Contracts and Unexpired Leases, (III) Granting the Purchaser the Protections Afforded to a Good Faith Purchaser, (IV) Approving Purchaser Protections in Connection With the Sale of the Lonafarnib and Lambda Assets, and (V) Granting Related Relief* [Docket No. 490] (the “Motion”), which included the proposed order for the sale of the Lonafarnib/Lambda Assets, and asset purchase agreements for the sale of the Lonafarnib/Lambda Assets (the “Lonafarnib/Lambda APAs”).

37. On August 21, 2024, the Court entered the *Revised Order (I) Authorizing the Sale of the Lonafarnib and Lambda Assets Free and Clear of Liens, Claims, Encumbrances, and Other Interests, (II) Authorizing the Assumption and Assignment of Executory Contracts and Unexpired*

*Leases, (III) Granting the Purchaser the Protections Afforded to a Good Faith Purchaser, (IV) Approving Purchaser Protections in Connection with the Sale of the Lonafarnib and Lambda Assets, and (V) Granting Related Relief* [Doc. 558] (the “Revised Lonafarnib/Lambda Sale Order”), which approved the sale to Eiger InnoTherapeutics, Inc. The sale of the Lonafarnib/Lambda Assets to Eiger InnoTherapeutics, Inc. closed on September 5, 2024

38. The marketing process conducted by SSG allowed the Debtors to maximize the value of the Debtors’ assets. Ultimately, SSG’s efforts resulted in the consummation of three very successful transactions that resulted in gross sale proceeds exceeding \$87.0 million for all of the Company’s assets, likely returning capital to equity holders. SSG’s robust and efficient marketing processes, experience in complex Chapter 11 cases, and strong knowledge of the biopharmaceutical industry resulted in an outcome that delivered significant value to stakeholders. Based on the services performed by SSG and the results obtained in this case, the compensation requested herein by SSG is reasonable under section 328 and 330 of the Bankruptcy Code.

39. Pursuant to the Engagement Agreement, SSG agreed to provide the following services in connection with any sale of the Debtors’ assets:

- a. Advise the Debtors on, and assist the Debtors in the preparation of, an information memorandum describing the Debtors and its management and financial status for use in discussions with prospective purchasers and assist in the due diligence process for a potential Sale Transaction;
- b. Assist the Debtors in developing a list of suitable potential buyers who will be contacted on a discreet and confidential basis after approval by the Debtors;
- c. Coordinate the execution of confidentiality agreements for potential buyers wishing to review the information memorandum;
- d. Assist the Debtors in coordinating management calls and site visits for interested buyers and work with the management team to develop appropriate presentations for such calls and visits;

- e. Solicit competitive offers from potential buyers;
- f. Advise and assist the Debtors in structuring the Sale Transaction, negotiating the Sale Transaction agreements with potential buyers and evaluating the proposals from potential buyers, including, without limitation, advising and negotiating with respect to Sale Transaction structures that include, as may be necessary or desirable, licenses, milestone and royalty payments and/or assignments of intellectual property;
- g. Provide testimony in support of the Sale Transaction, as necessary;
- h. Otherwise assist the Debtors, its attorneys and accountants, as necessary, through closing on a best efforts basis.

### **RELIEF REQUESTED**

40. By this Application, SSG seeks final allowance of compensation for services rendered from April 1, 2024, through September 5, 2024 in the total amount of \$2,727,387.99

41. Pursuant to the SSG Retention Order, the Court approved the following fee and expense structure set forth in the Engagement Agreement (the “Fee and Expense Structure”):

- Monthly Fees. Monthly fees (the “Monthly Fees”) of \$50,000 per month payable beginning May 1, 2023 and on the first (1st) of each month thereafter throughout the Engagement Term.
- Transaction Fee. Upon the consummation of a Sale Transaction to any party, SSG shall be entitled to a fee (the “Transaction Fee”), payable in cash, in federal funds via wire transfer or certified check, at and as a condition of closing of such Sale Transaction and as a direct carveout from proceeds and cash, prior in right to any pre- and post-petition secured debt, equal to the greater of (a) \$600,000; or (b) three percent (3.0%) of Total Consideration (as such term is hereafter defined).
- The Transaction Fee shall be reduced by 50% of the Monthly Fees paid, beginning July 1, 2024. No credit shall be provided for the Initial Fee or Monthly Fees paid prior to July 1, 2024.

42. In addition to the foregoing Monthly Fees and Transaction Fee noted above whether or not a Sale Transaction is consummated, SSG will be entitled to reimbursement for all of SSG’s reasonable and documented out-of-pocket expenses incurred in connection with the subject matter

of this Engagement Agreement; provided that such expenses shall not exceed \$5,000 without the Company's prior written approval.

43. The consummation of the sale(s) of the Debtors' assets resulted in SSG being entitled to the Transaction Fee in the amount of \$2,518,000.00, calculated as the greater of \$600,000.00 or 3.0% of Total Consideration, less 50% of the Monthly Fees paid, beginning July 1, 2024. The Transaction Fee(s) were paid following each respective sale closing in accordance with the Engagement Agreement and the SSG Retention Order, subject to the Court's approval of SSG's Final Fee Application.

44. During the Application Period, SSG was entitled to Monthly Fees totaling \$200,000.00 for May, June, July and August 2024. All of the Monthly Fees were paid throughout the Application Period.

45. SSG further requests reimbursement of the actual and necessary expenses expended on behalf of the Debtors during the Application Period in the amount of \$9,387.99, a summary of which is attached hereto as **Exhibit C**.

46. Pursuant to the SSG Retention Order, SSG summarized the tasks that it performed during these Chapter 11 Cases. The summary is not intended to be a detailed description of the work performed but merely a guideline offered to the Court and other interested parties with respect to the services performed by SSG during these Chapter 11 Cases. Day-to-day services and the time expended in performing such services during the Application Period are set forth in the timesheets, attached hereto and made a part hereof as **Exhibit D**.

47. SSG's professionals that worked full time on this assignment were:

- J. Scott Victor – Managing Director
- Teresa C. Kohl – Managing Director



- Craig D. Warznak – Senior Vice President
- Alexander D. Lamm – Senior Associate
- Nicholas A. Vernacchio – Senior Analyst

### **COMPLIANCE WITH GUIDELINES**

48. The Applicant believes that this Application substantially complies with the Local Rules and the U.S. Trustee guidelines for fee applications. To the extent there has not been material compliance with any particular guidelines or rules, the Applicant respectfully requests a waiver of such guidelines or rules.

49. This is the Applicant's First and Final Application pursuant to sections 328, 330 and 331 of the Bankruptcy Code for allowance of fees and reimbursement of expenses in this case. The Applicant has made no prior or other application to this or any other Court for the relief requested herein.

50. In accordance with the Local Rules, the undersigned has reviewed the requirements of the Local Rules and certifies to the best of his information, knowledge, and belief that this Application complies with the Local Rules, except as otherwise waived or modified by the SSG Retention Order.

### **CONCLUSION**

51. SSG submits that the services provided to the Debtors during the Application Period were necessary and appropriate given the complexity of this Chapter 11 Case, the significant assets and issues involved, the nature and extent of services provided and the cost of comparable services outside of bankruptcy. Accordingly, SSG submits that approval of the compensation sought for the Application Period is appropriate and should be approved.

52. WHEREFORE, SSG respectfully requests that the Court enter an order (i) allowing final compensation in the amount of \$2,718,000.00 for services rendered as investment banker on behalf of the Debtors during the Application Period plus \$9,387.99 in reimbursable expenses and approving payment for the Transaction Fees in the amount of \$2,518,000.00, Monthly Fees in the amount of \$200,000.00, plus \$9,387.99 in reimbursable expenses and (ii) granting such other and further relief as the Court deems just and proper.

Dated: September 27, 2024

West Conshohocken, PA

**SSG Advisors, LLC**



J. Scott Victor  
Managing Director  
SSG Advisors, LLC  
300 Barr Harbor Drive, Suite 420  
West Conshohocken, PA 19428  
Tel: (610) 940-5802

*Investment Bankers for the Debtors*

**EXHIBIT A**  
**Engagement Agreement**



SSG®

ADVISORS, LLC

March 22, 2024

David Apelian, MD, PhD  
Chief Executive Officer  
Eiger BioPharmaceuticals  
2155 Park Boulevard  
Palo Alto, CA 94306

Dear Dr. Apelian:

This agreement ("Engagement Agreement") will serve as the contract between Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") and SSG Advisors, LLC ("SSG") regarding the retention of SSG as exclusive investment banker to Eiger for the purposes outlined in this Engagement Agreement. SSG's responsibilities hereunder involve providing investment banking services to the Company, on an exclusive basis, focusing on a Sale Transaction (as defined below).

A. **SSG's Role:**

1. Sale Services

- Advise the Company on, and assist the Company in the preparation of, an information memorandum describing the Company and its management and financial status for use in discussions with prospective purchasers and assist in the due diligence process for a potential Sale Transaction;
- Assist the Company in developing a list of suitable potential buyers who will be contacted on a discreet and confidential basis after approval by the Company;
- Coordinate the execution of confidentiality agreements for potential buyers wishing to review the information memorandum;
- Assist the Company in coordinating management calls and site visits for interested buyers and work with the management team to develop appropriate presentations for such calls and visits;
- Solicit competitive offers from potential buyers;
- Advise and assist the Company in structuring the Sale Transaction, negotiating the Sale Transaction agreements with potential buyers and evaluating the proposals from potential buyers, including, without limitation, advising and negotiating with respect to Sale Transaction structures that include, as may be necessary or desirable, licenses, milestone and royalty payments and/or assignments of intellectual property;

Dr. David Apelian  
March 22, 2024  
Page 2

- Provide testimony in support of the Sale Transaction, as necessary;
- Otherwise assist the Company, its attorneys and accountants, as necessary, through closing on a best efforts basis.

In performing the services described above, the Company will furnish or cause to be furnished to SSG such information as SSG reasonably believes appropriate to the execution of its engagement hereunder (all such information so furnished being the "Information"). The Company represents to SSG that all Information furnished by it or its agents will be complete and correct in all material respects, to the best of its knowledge, and that until the expiration of SSG's engagement hereunder, it will advise SSG promptly of the occurrence of any event or any other change known by it or its agents that results in the Information ceasing to be complete and correct in all material respects. The Company recognizes and confirms that SSG: (a) will use and rely primarily on the Information and on information available from generally recognized public sources in performing the services contemplated hereby without having independently verified any of the same; (b) does not assume responsibility for accurateness or completeness of the Information and such other information; and (c) will not make an appraisal of any of the assets or liabilities of the Company. For the purposes of this Engagement Agreement, "known to," "to the knowledge of" or similar phrases means the actual knowledge, after due inquiry, of the executive officers of Eiger.

The Company agrees that SSG shall be its exclusive investment banker in connection with any Sale Transaction undertaken with respect to the Company during the Engagement Term, as defined below, of this Engagement Agreement. The Company agrees that, during the Engagement Term, SSG shall assist and advise the Company in its negotiations with all prospective purchasers and investors in connection with any Sale Transaction. In that regard, the Company agrees to identify to SSG: (a) all prospective purchasers and investors who have been in contact with the Company prior to the date hereof and (b) all prospective purchasers and investors who come in contact with the Company during the Engagement Term.

SSG will consult with and advise the Company with respect to the financial aspects of any proposed Sale Transaction, including price, terms, and conditions of a Sale Transaction. SSG will not, however, have any authority to bind the Company with respect to any proposed Sale Transaction. Likewise, nothing contained herein shall require the Company to accept the terms of any proposal and the Company shall at all times have the right in its sole and absolute discretion to reject any proposed Sale Transaction regardless of the terms proposed.

**B. SSG's Compensation**

As compensation for providing the foregoing services, SSG shall receive the following:

1. Initial Fee. An initial fee (the "Initial Fee") equal to \$100,000 due upon signing this Engagement Agreement;

Dr. David Apelian  
March 22, 2024  
Page 3

2. **Monthly Fees.** Monthly fees (the “Monthly Fees”) of \$50,000 per month payable beginning May 1, 2023 and on the first (1st) of each month thereafter throughout the Engagement Term (as such term is hereafter defined).
3. **Transaction Fee.** Upon the consummation of a Sale Transaction to any party, SSG shall be entitled to a fee (the “Transaction Fee”), payable in cash, in federal funds via wire transfer or certified check, at and as a condition of closing of such Sale Transaction and as a direct carveout from proceeds and cash, prior in right to any pre- and post-petition secured debt, equal to the greater of (a) \$600,000; or (b) three percent (3.0%) of Total Consideration (as such term is hereafter defined).

The Transaction Fee shall be reduced by 50% of the Monthly Fees paid, beginning July 1, 2024. No credit shall be provided for the Initial Fee or Monthly Fees paid prior to July 1, 2024.

4. In addition to the foregoing Initial Fee, Monthly Fee and Transaction Fee noted above whether or not a Sale Transaction is consummated, SSG will be entitled to reimbursement for all of SSG’s reasonable and documented out-of-pocket expenses incurred in connection with the subject matter of this Engagement Agreement; provided that such expenses shall not exceed \$5,000 without the Company’s prior written approval.

### C. **Definitions**

For the purpose of this Engagement Agreement:

**Sale Transaction** means and includes any transaction involving the sale or transfer, licensing, directly or indirectly, of all or substantially all of the assets, intellectual property, drug development work in progress, or equity of Company. For the avoidance of doubt, the Sale Transaction shall not include any sale, sublicense, or transfer of Zokinvy consummated prior to entry into a potential chapter 11 bankruptcy process.

**Total Consideration** shall mean the purchase price paid at the time of the effective date of the Sale after giving effect to the Sale Transaction for the equity, assets or any portion of either, plus the assumption or payoff of indebtedness (secured and unsecured, but excluding trade, vendor or similar credit extended to the Company in connection with conducting its business operations or other debt that is not debt for borrowed money) and/or payables, equipment leases (operating and capitalized), real estate leases (operating and capitalized) as well as the value of any asset left behind in the estate, plus any milestone and royalty payments to be received in the future, when and if received.

**Confidential Information** includes all non-public scientific, technical, business or financial information possessed or obtained by, developed for or given to Company which is treated by Company as confidential or proprietary, whether or not labeled “Confidential.”

For purposes of computing any fees payable to SSG hereunder, non-cash consideration shall be valued as follows: (a) publicly traded securities shall be

Dr. David Apelian  
March 22, 2024  
Page 4

valued in the manner specified in the definitive agreement for the Sale Transaction, or, if not so specified, at the average of their closing prices (as reported in The Wall Street Journal) for the five (5) trading days prior to the closing of the Sale Transaction; and (b) any other non-cash consideration shall be valued at the fair market value thereof as determined in good faith by the Company and SSG. If such aggregate consideration may be increased by contingent payments such as an “earnout” or other monetary agreement in the transaction, the portion of SSG’s fee relating thereto shall be calculated and paid when and as such contingent payments or other monetary amounts are received.

**Transaction Fee** shall have the definition given to such term in paragraph B(3).

D. **Term of Engagement**

This Engagement Agreement shall remain in force (the “Engagement Term”) for a period of six (6) months from the date of signing this Engagement Agreement, and may extended thereafter upon prior written consent of the parties. Either party may terminate this Engagement Agreement upon five (5) days prior written notice to the other; provided, however, that this Engagement Agreement shall automatically terminate immediately upon the closing of a Sale Transaction. Upon the termination of this Engagement Agreement, neither party shall have any further obligations to the other except that: (a) termination of the Engagement Agreement shall not affect SSG’s right to indemnification under the Indemnification paragraph below; (b) the Company shall remain obligated to pay SSG any unpaid Monthly Fees and to reimburse SSG for any expenses incurred through the date of the termination of the Engagement Agreement; and (c) if a Sale Transaction is consummated within nine (9) months (“Trailer Term”) of the termination of this Engagement Agreement with a party with whom SSG had contract during the Engagement Term, the Company shall remain obligated to pay a Transaction Fee, as calculated above; *provided*, however, that if this Engagement Agreement has been terminated for gross negligence, bad faith, actual fraud, or willful misconduct by SSG in the performance of SSG’s duties under this Engagement Agreement and such conduct is determined as gross negligence, bad faith, actual fraud, or willful misconduct by an order of a court on final judgment, the Company shall have no further obligations to pay any additional fees. Sections B, D, E, F and G (entitled Compensation, Term of Engagement, Indemnification, Miscellaneous, and Scope of SSG’s Duties, respectively) of this Engagement Agreement shall survive the expiration or termination of this Engagement Agreement indefinitely.

E. **Indemnification**

The Company hereby acknowledges and agrees to the indemnification arrangements between the parties hereto as described on Attachment A hereto, which Attachment is incorporated herein and forms an integral part hereof.

F. **Confidential Information**

SSG acknowledges that Eiger is and will remain the sole owner of Confidential Information. SSG will take all commercially reasonable precautions to protect the confidentiality of Confidential Information, and will not disclose or use any Confidential Information except with Eiger’s knowledge and as necessary to perform the Services. In particular, SSG may disclose Confidential Information to SSG

Dr. David Apelian  
March 22, 2024  
Page 5

personnel who need to know such Confidential Information in order to provide the Services and who are obligated to protect the confidentiality of such Confidential Information under terms substantially similar to or more stringent than those set forth in this Section F. SSG may disclose Confidential Information to a governmental authority or by order of a court of competent jurisdiction, provided that the disclosure is subject to all applicable governmental or judicial protection available for like material and reasonable advance notice is given to Eiger. The obligations of non-disclosure will not apply to information which (a) was known to SSG at the time it was disclosed, other than by previous disclosure by Eiger, as evidenced by SSG's written records at the time of disclosure, (b) is at the time of disclosure or later becomes publicly known under circumstances involving no breach of this Agreement, or (c) is lawfully and in good faith made available to SSG by a third party who did not derive it, directly or indirectly, from Eiger.

G. **Miscellaneous**

No fee payable to any other financial advisor or finder by the Company in connection with the subject matter of this Engagement Agreement shall reduce or otherwise affect any fee payable to SSG hereunder. This Engagement Agreement sets forth the entire understanding of the parties relating to the subject matter hereof and supersedes and cancels any prior communications, understandings and agreements between the parties hereto. This Engagement Agreement cannot be modified or changed, nor can any of its provisions be waived, except by written agreement signed by both parties. The benefits of this Engagement Agreement shall inure to the respective successors and assigns of the parties hereto and of the Indemnified Parties and their respective successors, assigns and representatives, and the obligations and liabilities assumed in this Engagement Agreement by the parties hereto shall be binding upon their respective successors and assigns.

This Engagement Agreement may be executed in any number of counterparts, which counterparts, taken together, shall constitute one and the same Engagement Agreement.

H. **Scope of Duties**

The Company hereby acknowledges and agrees that: (a) it has retained SSG for the purposes set forth in the Engagement Agreement and that the rights and obligations of the parties hereto are contractual in nature, and (b) SSG has not made any warranties or guarantees of any nature with respect to the success or satisfactory conclusion of any Sale Transaction or as to the economic, financial or other results which may be obtained or experienced by the Company as a result thereof.

I. **Bankruptcy Court Proceedings**

In the event the Company files one or more Bankruptcy Cases during the Engagement Term, the Company shall use its commercially reasonable efforts to have SSG employed upon the same or substantially similar terms and shall have this Engagement Agreement and SSG's retention as the Company's exclusive investment banker approved by a Court of competent jurisdiction.



Dr. David Apelian  
March 22, 2024  
Page 6

J. **Other Matters**

SSG has the right, following a Sale Transaction closing, to place advertisements in financial and other newspapers and journals and to send email advertising at its own expense describing its services to the Company hereunder.

In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), SSG is required to obtain, verify and record information that identifies its clients, which information may include the name and address of the Company, and its senior management team as well as other information that will allow SSG to properly identify its clients. Additionally, SSG maintains important disclosures on its web site [www.ssgca.com](http://www.ssgca.com). These disclosures may be updated periodically on an as-needed basis. The Company agrees to accept and receive all of these disclosures by electronically accessing the website referenced above and acknowledges that printed hard copies of these disclosures are available upon request by contacting SSG directly at (610) 940-1094.

K. **Securities Platform**

All transactions involving the sale or purchase of any security (as defined by the Securities Exchange Act of 1934 or the rules and regulations promulgated there under) are offered through SSG Capital Advisors, LLC. ("SCA") which is an affiliated registered Broker-Dealer in good standing with the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC"). Principals of SSG are registered representatives of SCA. Therefore, SCA is included collectively as "SSG" with all the rights and obligations thereto under the terms of this Engagement Agreement.

To the extent a Transaction Fee is payable to SSG in connection with Sale Transaction constituting the purchase or sale of any security (as defined by the Securities Exchange Act of 1934 or the rules and regulations promulgated there under), such Transaction Fee (excluding the Initial Fee and Monthly Fees) shall be specifically paid to SCA. In addition to the Initial Fee and Monthly Fees, under no circumstances will the Company be obligated to pay any fees in an aggregate amount in excess of the Transaction Fee. Payment of the fee to SCA shall constitute and be deemed payment of the Transaction Fee under the Engagement Agreement.

Dr. David Apelian  
March 22, 2024  
Page 7

Any amendment, modification or other changes to this Engagement Agreement must be in writing and signed by both parties to be enforceable.

Please indicate your acceptance of the foregoing by executing and returning the enclosed copy of this letter.


**SSG ADVISORS, LLC**

By:   
\_\_\_\_\_  
J. Scott Victor  
Managing Director

  
\_\_\_\_\_  
Teresa C. Kohl  
Managing Director

ACCEPTED:

**EIGER BIOPHARMACEUTICALS, INC.**

By:   
\_\_\_\_\_  
David Apelian, MD, PhD  
Chief Executive Officer

3/22/2024  
\_\_\_\_\_  
Date

Dr. David Apelian  
March 22, 2024  
Page 8

## **ATTACHMENT A INDEMNIFICATION PROVISIONS**

The Company agrees to indemnify, defend and hold harmless SSG or SCA, and their affiliates, the respective partners, members, directors, officers, agents and employees of SSG, SCA, and their affiliates and each other person, if any, controlling SSG, SCA, and their affiliates (the foregoing being referred to herein individually as an "Indemnified Party" and collectively as the "Indemnified Parties") from and against any and all losses, claims, damages, liabilities or costs, as and when incurred, to which such Indemnified Party may become subject to or which are asserted against any Indemnified Party, directly or indirectly, in any way related to SSG acting for the Company under the Engagement Agreement of which this Attachment A forms a part, including, without limitation, in connection with: (a) any act or omission by SSG related to its engagement as financial advisor under the Engagement Agreement; or (b) SSG's acceptance, or its performance or non-performance, of its obligations under said Engagement Agreement. The Company will reimburse the Indemnified Parties for any reasonable and documented legal or other expenses incurred by them, as and when incurred, in connection with investigating, preparing or defending any such losses, claims, damages or liabilities or any action in respect thereof, whether or not in connection with pending or threatened litigation, and whether or not any Indemnified Party is a party thereto; provided, however, that the Company shall not be liable under the foregoing indemnity agreement in respect of any liability to the extent that such liability is found in a final judgment by a court of competent jurisdiction, not subject to further appeal, to have resulted from SSG's gross negligence, bad faith, actual fraud, or willful misconduct in the performance of its duties under said Engagement Agreement (and in such event, expenses of SSG paid by the Company in advance that are reasonably attributable thereto shall be promptly reimbursed in full to the Company). The Company agrees that reliance by SSG on any publicly-available information, the information supplied by the Company to SSG in connection with said Engagement Agreement or any directions furnished by the Company shall not constitute gross negligence, bad faith or willful misconduct by SSG.

In order to provide for just and equitable contribution, if a claim for indemnification is made pursuant to said Engagement Agreement but it is found in a final judgment by a court of competent jurisdiction, not subject to further appeal, that such indemnification may not be enforced in such case, the Indemnified Parties, on the one hand, and the Company, on the other hand, shall each contribute to the amount paid or payable as a result of such losses, claims, damages or liabilities in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties, on the one hand, and the Company, on the other hand, and the relative benefits to the Indemnified Parties, on the one hand, and the Company, on the other hand, arising out of the particular matter or transaction which gave rise to such loss, claim, damage, liability or costs, and all other relevant equitable considerations shall also be taken into account. No person found liable for a fraudulent misrepresentation shall be entitled to contribution from any person who is not also found liable for such fraudulent misrepresentation.

The provisions of this Attachment A shall survive any termination of said Engagement Agreement.

**EXHIBIT B**  
**Retention Order**




CLERK, U.S. BANKRUPTCY COURT  
NORTHERN DISTRICT OF TEXAS

**ENTERED**

THE DATE OF ENTRY IS ON  
THE COURT'S DOCKET

The following constitutes the ruling of the court and has the force and effect therein described.

Signed May 13, 2024

  
United States Bankruptcy Judge

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC.,  
*et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**ORDER AUTHORIZING THE  
EMPLOYMENT AND RETENTION OF SSG ADVISORS, LLC  
AS INVESTMENT BANKER EFFECTIVE AS OF THE PETITION DATE**

Upon the application (the "Application")<sup>2</sup> of the debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the "Debtors"), for entry of an order (this "Order") (a) authorizing the employment and retention of SSG Advisors LLC ("SSG") as investment bankers for the Debtors, effective as of the Petition Date (as defined below), in accordance with the terms and conditions of the Engagement Agreement; (b) approving the terms of SSG's employment, including the proposed compensation arrangement and indemnification provisions

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2100 Ross Avenue, Dallas, Texas 75201.

<sup>2</sup> Capitalized terms used but not defined herein shall have the meaning provided in the Application.



248004024051300000000016

set forth therein, under section 328(a) of the Bankruptcy Code; (c) exempting SSG from time-keeping requirements; and (d) granting related relief, each as more fully set forth in the Application; and upon consideration of the Application and Victor Declaration; and this Court having jurisdiction over this matter pursuant to 28 U.S.C. § 1334; and this matter being a core proceeding within the meaning of 28 U.S.C. § 157(b)(2); and the Court being able to issue a final order consistent with Article III of the United States Constitution; and the Court having found that venue of this proceeding and the Motion in this district being proper pursuant to 28 U.S.C. §§ 1408 and 1409; and appropriate notice of and opportunity for a hearing on the Application having been given; and the relief requested in the Application being in the best interests of the Debtors' estates, their creditors and other parties in interest; and the Court having determined that the legal and factual bases set forth in the Application establish just cause for the relief granted herein; and after due deliberation and sufficient cause appearing therefor, it is

**HEREBY ORDERED THAT:**

1. Pursuant to sections 327(a) and 328(a) of the Bankruptcy Code, the Debtors are hereby authorized to retain SSG as investment banker to the Debtors in these chapter 11 cases effective as of the Petition Date on the terms and conditions set forth in the Application and the Engagement Agreement attached to the Application as **Exhibit B**, as modified by this Order.

2. Subject to the terms of this Order and any modifications to the Engagement Agreement set forth in this Order, all terms and conditions of the Engagement Agreement, including, without limitation, the Initial Fee, Monthly Fee, and Transaction Fees, are reasonable terms and conditions of employment and hereby approved.

3. SSG shall file a final and sole fee application for final allowance of compensation and reimbursement of expenses pursuant to procedures set forth in sections 330 and 331 of the

Bankruptcy Code and any other applicable procedures established by the Court; *provided, however,* the fees payable to SSG pursuant to the Engagement Agreement shall be subject to review only pursuant to the standards set forth in section 328(a) of the Bankruptcy Code and shall not be subject to the standard of review set forth in section 330 of the Bankruptcy Code.

4. Notwithstanding the preceding paragraph, the U.S. Trustee and the Court shall retain the right to object to compensation and fees and expenses to be paid to SSG pursuant to the Application and the Engagement Agreement based on the reasonableness standard provided for in section 330 of the Bankruptcy Code, and the Court shall consider any such objection by the U.S. Trustee under section 330 of the Bankruptcy Code; *provided* that reasonableness for this purpose shall include, among other things, an evaluation by comparing the fees payable in this case to the fees paid to other investment banking firms for comparable services in other chapter 11 cases and outside of chapter 11 cases, and shall not be evaluated primarily on the basis of time committed or the length of these cases.

5. SSG is hereby authorized to maintain records (in summary format) of the services rendered for the Debtors, including summary descriptions of those services and the identity of the professionals who provided those services. SSG will submit, with any final fee application a narrative summary of services rendered and will identify each professional rendering services, the category of services rendered, and the total amount of compensation requested by SSG, but shall not be required to keep detailed time records.

6. Notwithstanding anything in the Application or the Engagement Agreement to the contrary, SSG shall (i) to the extent that SSG uses the services of independent contractors, subcontractors or employees of foreign affiliates or subsidiaries (collectively, the “Contractors”) in these cases, SSG shall pass-through the cost of such Contractors to the Debtors at the same rate

that SSG pays the Contractors, (ii) seek reimbursement for actual costs only, (iii) ensure that the Contractors are subject to the same conflict checks as required for SSG, and (iv) file with the Court such disclosures as required by Bankruptcy Rule 2014.

7. In the event that, during the pendency of these cases, SSG seeks reimbursement for any attorneys' fees and/or expenses, the invoices and supporting time records from such attorneys, appropriately redacted to preserve applicable privileges, shall be included in SSG's fee application and such invoices and time records shall be in compliance with the Local Rules, and shall be subject to the U.S. Trustee Guidelines and approval of the Court under the standards of Bankruptcy Code sections 330 and 331, without regard to whether such attorney has been retained under Bankruptcy Code section 327; *provided, however*, that SSG shall not seek reimbursement from the Debtors' estates for any fees incurred in defending any of SSG's fee application in these bankruptcy cases.

8. To the extent the Debtors wish to expand the scope of services under the Engagement Agreement, the Debtors shall seek further approval from this Court.

9. The indemnification provisions of the Engagement Agreement are approved, subject during the pendency of these cases to the following:

(i) Subject to the provisions of subparagraphs (b) and (c) below, the Debtors are authorized to indemnify, and shall indemnify, SSG and the other Indemnified Parties for any claims arising out of or related to SSG's engagement under, or any matter referred to in, the Engagement Agreement and/or the services to be provided by SSG as specified in this Application, but not for any claim arising from, related to, or in connection with SSG's post-petition performance of any other services other than those in connection with the engagement, unless such post-petition services and indemnification therefor are approved by this Court;

(ii) the Debtors shall have no obligations to indemnify SSG for any claim or expense that is either (i) judicially determined (the determination having become final) to have resulted primarily from SSG's actual fraud, gross negligence, bad faith, breach of fiduciary duty (if any), self-dealing (if found to be applicable), or willful misconduct, or (ii) settled prior to a judicial determination as to SSG's actual fraud, gross negligence, bad faith, breach of fiduciary duty (if any), self-dealing (if found to be applicable), or willful



misconduct, but determined by this Court, after notice and a hearing pursuant to subparagraph (c) infra, to be a claim or expense for which SSG is not entitled to receive indemnity under the terms of the Application; and

(iii) if, before the earlier of (i) the entry of an order confirming a chapter 11 plan in these cases (that order having become a final order no longer subject to appeal), and (ii) the entry of an order closing these chapter 11 cases, SSG believes that it is entitled to the payment of any amounts by the Debtors on account of the Debtors' indemnification, reimbursement, and contribution obligations under the Engagement Agreement or the Application, including, without limitation, the advancement of defense costs, SSG must file an application in this Court, and the Debtors may not pay any such amounts to SSG before the entry of an order by this Court approving the payment. This subparagraph (c) is intended only to specify the period of time under which the Court shall have jurisdiction over any request for fees and expenses by SSG for indemnification, and not as a provision limiting the duration of the Debtors' obligation to indemnify or provide contribution or reimbursement to SSG.

10. The Debtors and SSG are authorized to take all actions necessary to effectuate the relief granted pursuant to this Order in accordance with the Application.

11. For the avoidance of doubt, the Debtors are authorized to pay SSG its Monthly Fees without the necessity for monthly or interim applications for compensation.

12. Any objection to the Application, including any claim that SSG is precluded from assisting the Debtors in these chapter 11 cases under Bankruptcy Code sections 327 or 328 that arises from a relationship disclosed in the Victor Declaration is waived by any creditor or party in interest who received notice of the Application and failed to raise that objection, and such party shall be deemed to have consented to the Debtors' retention of SSG under the terms set forth in the Application and any attachments to the same and shall be forever barred and estopped from asserting any objection to the Application or the Debtors' retention of SSG under the terms set forth in the Application and any attachments to the same.

13. SSG will review its files periodically during the pendency of these chapter 11 cases to ensure that no conflicts or other disqualifying circumstances exist or arise. If any new relevant

facts or relationships are discovered or arise, SSG will promptly file a supplemental declaration, as required by Bankruptcy Rule 2014(a).

14. SSG shall make reasonable efforts to avoid any duplication of services provided by any of the Debtors' other retained professionals in these chapter 11 cases.

15. Notwithstanding anything to the contrary herein, any payment to be made by the Debtors pursuant to the authority granted herein shall be subject to and in compliance with any orders entered by the Court authorizing the Debtors' use of cash collateral and/or any budget in connection therewith.

16. Notice of the Application as provided therein shall be deemed good and sufficient notice of such Application and the requirements of Bankruptcy Rule 6004(a) and the Local Rules are satisfied by such notice.

17. Notwithstanding Bankruptcy Rule 6004(h), the terms and conditions of this Order shall be immediately effective and enforceable upon its entry.

18. The Debtors are authorized to take all actions necessary to effectuate the relief granted in this Order in accordance with the Application.

19. Notwithstanding any term in the Engagement Letter to the contrary, this Court retains exclusive jurisdiction with respect to all matters arising from or related to the implementation, interpretation, and enforcement of this Order.

**### END OF ORDER ###**

Submitted By:

**SIDLEY AUSTIN LLP**

Thomas R. Califano (TX Bar No. 24122825)  
William E. Curtin (admitted *pro hac vice*)  
Anne G. Wallice (admitted *pro hac vice*)  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: tom.califano@sidley.com  
wcurtin@sidley.com  
anne.wallice@sidley.com

*and*

Charles M. Persons (TX Bar No. 24060413)  
2021 McKinney Avenue, Suite 2000  
Dallas, Texas 75201  
Telephone: (214) 981-3300  
Facsimile: (214) 981-3400  
Email: cpersons@sidley.com

*Attorneys for the Debtors and Debtors in Possession*

**EXHIBIT C**  
**Expense Detail**

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*

*Expense Detail  
 SSG Advisors, LLC*

<b>Date</b>	<b>Professional</b>	<b>Expense Type</b>	<b>Event</b>	<b>Amount</b>
28-Mar-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	\$ 862.00
28-Mar-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	35.00
2-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	19.00
3-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	151.48
4-Apr-24	J. Scott Victor	Parking & Tolls	Court Hearing	56.00
4-Apr-24	J. Scott Victor	Lodging	Court Hearing	9.46
4-Apr-24	J. Scott Victor	Lodging	Court Hearing	1,646.61
9-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	158.89
17-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	817.00
17-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	35.00
22-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	20.18
23-Apr-24	J. Scott Victor	Parking & Tolls	Court Hearing	56.00
23-Apr-24	J. Scott Victor	Travel Meals	Court Hearing	91.01
23-Apr-24	J. Scott Victor	Lodging	Court Hearing	49.66
23-Apr-24	J. Scott Victor	Lodging	Court Hearing	816.81
24-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	139.09
24-Apr-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	156.48
13-May-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	20.00
27-Jun-24	Craig D. Warznak	Other Transit/Car Rental	Court Hearing	1,291.95
27-Jun-24	Craig D. Warznak	Other Transit/Car Rental	Court Hearing	44.47
27-Jun-24	Craig D. Warznak	Other Transit/Car Rental	Court Hearing	10.06
27-Jun-24	Craig D. Warznak	Lodging	Court Hearing	882.59
27-Jun-24	Craig D. Warznak	Other Transit/Car Rental	Court Hearing	130.76
27-Jun-24	Craig D. Warznak	Parking & Tolls	Court Hearing	56.00
14-Aug-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	761.00
14-Aug-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	35.00
20-Aug-24	J. Scott Victor	Lodging	Court Hearing	679.92
21-Aug-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	139.09
21-Aug-24	J. Scott Victor	Parking & Tolls	Court Hearing	56.00
21-Aug-24	J. Scott Victor	Other Transit/Car Rental	Court Hearing	156.48
19-Sep-24	J. Scott Victor	Lodging	Court Hearing	5.00

**Total \$ 9,387.99**

**EXHIBIT D**  
**Time Sheets**

*Eiger BioPharmaceuticals - Case No. 24-80040 (SGL)**J. Scott Victor; Managing Director**SSG Advisors; LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
4/1/2024	Weekly process update call with Debtor team; Review docket; Emails with Debtor team; Calls/emails with buyers; review marketing materials; Internal discussion	6.0
4/2/2024	Review docket and bankruptcy filings; Emails with Debtor team; Calls/emails with buyers; Internal discussion; Call with Debtor Team; Travel to Dallas; TX.	9.5
4/3/2024	Calls/emails with buyers; Meeting with Debtor team; Attend first day hearing in Dallas and testimony; Internal discussion	8.5
4/4/2024	Calls/emails with buyers; Review marketing process launch; Review NDAs; Emails with Debtor team; Internal discussion; Travel from Dallas to Philadelphia	10.0
4/5/2024	Calls/emails with buyers; Calls/emails with Debtor team; Calls/emails with stakeholders; Review buyer outreach/marketing; Internal discussion	6.5
4/6/2024	Emails with buyers; Emails with Debtor team; Internal discussion	1.5
4/7/2024	Emails with buyers; Emails with Debtor team; Internal discussion	1.5
4/8/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review buyer outreach/marketing; Review process update report; Weekly advisor call with Debtor team and Board	7.0
4/9/2024	Call with buyer and stakeholder; Stakeholder follow up; Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	5.0
4/10/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion; Call with counsel for potential buyer	5.5
4/11/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Call with lender; Internal discussion	7.0
4/12/2024	Calls/emails with buyers; Calls/emails with Debtor team; Weekly advisor call with Debtor team and Board; Auction prep and logistics review; Internal discussion	6.5
4/13/2024	Emails with buyers; Emails with Debtor team; Auction prep; Internal discussion	2.0
4/14/2024	Buyer emails; Emails with Debtor team; Emails with stakeholder; Auction prep; Internal discussion	2.5
4/15/2024	Call with stakeholder and Debtor team; Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Weekly advisor call with Debtor team and Board; Review bids; Review diligence status; Auction prep; Internal discussion	7.0
4/16/2024	Review and qualify bids with Debtor team; Calls/emails with buyers; Calls/emails with Debtor team; Call with lender; Auction prep; Internal discussion	7.5
4/17/2024	Auction prep; Attend auction Zoom for Zokinvy; Calls/emails with buyers; Calls/emails with Debtor team; Post-auction follow up; Internal discussion	8.5
4/18/2024	Calls/emails with buyers; Calls/emails with Debtor team; Buyer diligence call; Internal discussion	3.5
4/19/2024	Board call; Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	4.5
4/20/2024	Emails with buyers; Calls/emails with Debtor team; Internal discussion	2.0
4/21/2024	Emails with buyers; Calls/emails with Debtor team; Internal discussion	1.5
4/22/2024	Calls/emails with buyers; Calls/emails with Debtor team; Weekly advisor call with Debtor team and Board; Sale hearing review; Internal discussion; Fly to Dallas; TX; Dinner with Debtor Team	10.5
4/23/2024	Attend Zokinvy sale hearing - testimony; Calls/emails with buyers; Meeting with Debtor team; Internal discussion; Travel from Dallas to Philadelphia	10.5
4/24/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	3.0
4/25/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	3.5
4/26/2024	Calls/emails with buyers; Calls/emails with Debtor team; Board call; Call with lender; Internal discussion	5.0
4/27/2024	Emails with buyers; Emails with Debtor team	1.0
4/28/2024	Emails with buyers; Emails with Debtor team	0.5
4/29/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Weekly advisor call with Debtor team and Board; Internal discussion	3.5
4/30/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	2.0
5/1/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	2.0
5/2/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion; Attend status hearing via Webex	3.5
5/3/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update report; Call with lender	5.0
5/4/2024	Emails with buyers; Emails with Debtor team	1.0
5/5/2024	Emails with buyers; Emails with Debtor team	1.0
5/6/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Weekly advisor call with Debtor team and Board; Internal discussion	5.0
5/7/2024	Calls/emails with buyers; Calls/emails with Debtor team; Attend second day hearing Webex; Internal discussion	4.5
5/8/2024	Emails with buyers; Internal discussion	3.0
5/9/2024	Calls/emails with buyers; Calls/emails with Debtor team; Management meeting; Internal discussion	3.0

*Eiger BioPharmaceuticals - Case No. 24-80040 (SGL)*

*J. Scott Victor; Managing Director*

*SSG Advisors; LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
5/10/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Board call; Internal discussion	4.0
5/11/2024	Emails with buyers; Emails with Debtor team	0.5
5/12/2024	Emails with buyers; Emails with Debtor team	0.5
5/13/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Weekly advisor call with Debtor team and board; Review diligence status; Review buyer term sheet; Internal discussion	4.5
5/14/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review diligence status; Internal discussion	2.5
5/15/2024	Emails with buyers; Emails with Debtor team; Internal discussion	2.0
5/16/2024	Emails with buyers; Calls/emails with Debtor team; Internal discussion; Call with potential buyer	3.0
5/17/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Board call; Internal discussion	3.5
5/18/2024	Emails with buyers	0.5
5/19/2024	Emails with buyers	0.5
5/20/2024	Calls/emails with buyers; Calls/emails with Debtor team; Weekly advisor call with Debtor team and Board; Internal discussion	4.0
5/21/2024	Calls/emails with buyers; Management meeting; Calls/emails with Debtor team; Review draft asset purchase agreement; Review diligence; Review docket; Internal discussion	5.5
5/22/2024	Calls/emails with buyers; Management meeting; Calls/emails with Debtor team; Review draft asset purchase agreement; Review draft term sheet; Review diligence status; Internal discussion	5.0
5/23/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review diligence status; Internal discussion	2.5
5/24/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Board call; Review diligence status; Internal discussion	4.0
5/25/2024	Emails with buyers; Emails with Debtor team	0.5
5/26/2024	Emails with buyers; Emails with Debtor team	0.5
5/27/2024	Emails with buyers; Emails with Debtor team	0.5
5/28/2024	Calls/emails with buyers; Calls/emails with Debtor team; Management meeting; Internal discussion	4.5
5/29/2024	Calls/emails with buyers; Calls/emails with Debtor team; Attend hearing Webex; Review diligence status; Internal discussion	5.0
5/30/2024	Calls/emails with buyers; Calls/emails with Debtor team; Management meeting; Internal discussion	3.5
5/31/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Board call; Review diligence status; Internal discussion	4.0
6/1/2024	Emails with Debtor team	0.5
6/2/2024	Emails with Debtor team	0.5
6/3/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Weekly advisor call with Debtor and Board; Internal discussion	4.0
6/4/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review revised draft term sheet; Internal discussion	2.0
6/5/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review draft term sheet discussion with Debtor team; Internal discussion	4.0
6/6/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review diligence status; Internal discussion	2.0
6/7/2024	Calls/emails with buyers; Calls/emails with Debtor team; Management meeting; Review process update; Board call; Review revised draft asset purchase agreement; Internal discussion	5.5
6/8/2024	Emails with buyers; Internal discussion	0.5
6/9/2024	Emails with buyers; Internal discussion	0.5
6/10/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review process update; Weekly advisor call with Debtor and Board; Review draft asset purchase agreement; Calls with Debtor team re: stalking horse proposals and proposal review; Internal discussion	6.5
6/11/2024	Calls/emails with buyers; Calls/emails with Debtor team; Review stalking horse bids; Review bid summary presentation; Auction prep; Review final stalking horse proposal; Board call to select stalking horse bidder; Internal discussion	7.0
6/12/2024	Calls/emails with buyers; Calls/emails with Debtor team; Auction prep; Internal discussion	4.5
6/13/2024	Calls/emails with Debtor team; Review revised stalking horse asset purchase agreement; Auction prep and logistics; Internal discussion	4.0
6/14/2024	Calls/emails with buyers; Calls/emails with Debtor team; Board call; Auction prep and call with Debtor counsel; Internal discussion	5.0
6/15/2024	Auction prep; Emails with buyers; Emails with Debtor team; Internal discussion	2.0
6/16/2024	Auction prep; Emails with buyers; Emails with Debtor team; Internal discussion	2.0
6/17/2024	Calls/emails with buyers; Calls/emails with Debtor team; Auction prep; Attend auction Zoom for Avexitide; Board call to approve auction results; Internal discussion	7.5



*Eiger BioPharmaceuticals - Case No. 24-80040 (SGL)*

*J. Scott Victor; Managing Director*

*SSG Advisors; LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
6/18/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	2.0
6/19/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	1.5
6/20/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	1.0
6/21/2024	Calls/emails with buyers; Calls/emails with Debtor team; Board call; Diligence review; Internal discussion	3.5
6/22/2024	Calls/emails with buyers; Internal discussion	0.5
6/23/2024	Calls/emails with buyers; Internal discussion	0.5
6/24/2024	Calls/emails with buyers; Calls/emails with Debtor team; Call re: forecast review; Review process update; Weekly advisor call with Debtor and Board; Review and discuss revised term sheet; Review sale declaration; Internal discussion	6.0
6/25/2024	Calls/emails with buyers; Calls/emails with Debtor team; Internal discussion	2.0
6/26/2024	Calls/emails with buyers; Calls/emails with Debtor team; Attend sale hearing Webex for Avexitide; Internal discussion	3.0
6/27/2024	Emails with buyers; Emails with Debtor team; Review asset valuation analysis; Internal discussion	3.5
6/28/2024	Calls/emails with buyers; Emails with Debtor team; Board call; Review asset valuation analysis; Internal discussion	3.5
6/29/2024	Emails with buyers; Emails with Debtor team; Review asset valuation; Internal discussion	2.5
6/30/2024	Emails with buyers; Emails with Debtor team; Review asset valuation; Internal discussion	2.5
7/1/2024	Emails with professionals and management; Call with management regarding valuation; Review valuation; Call with buyer regarding draft APA; Internal discussion	4.0
7/2/2024	Emails/calls with professionals; Board call to discuss asset valuation; Review valuation; Emails/calls with buyers; Internal discussion; Call with potential buyer for L/L assets	4.5
7/3/2024	Review valuation; Review marketing materials for select assets	2.0
7/4/2024	Emails with management	0.5
7/5/2024	Emails with professionals; Review asset valuation analysis; Call with potential buyer for L/L assets	1.5
7/6/2024	Emails with Debtor Team; Call with counsel for potential buyer for L/L assets.	1.5
7/7/2024	Emails with Debtor Team	0.5
7/8/2024	Emails/calls with buyers; Emails with management; Emails with Debtor Team	2.0
7/9/2024	Emails/calls with buyers; Emails with Debtor Team	2.5
7/10/2024	Emails/calls with buyers; Emails with Debtor Team	2.0
7/11/2024	Emails with buyers; Emails with professionals and management; Review process update report; Internal discussion	3.5
7/12/2024	Review process update report; Weekly Board update call; Emails with buyers; Emails with Debtor Team	2.5
7/13/2024	Emails with Debtor Team	0.5
7/14/2024	Emails with Debtor Team	0.5
7/15/2024	Emails with buyers; Emails with Debtor Team; Board update call	4.0
7/16/2024	Emails with buyers; Emails with Debtor Team	1.0
7/17/2024	Emails with buyers; Emails/calls with Debtor Team; Call with potential buyer	3.0
7/18/2024	Emails with buyers; Emails with Debtor Team	2.0
7/19/2024	Emails/calls with buyers; Weekly Board update call; Buyer DD call with management; Internal discussion	3.5
7/20/2024	Emails with buyers; Emails with Debtor Team	1.0
7/21/2024	Emails with buyers; Emails with Debtor Team	1.5
7/22/2024	Emails with buyers; Emails with Debtor team; Internal discussion	1.5
7/23/2024	Emails/calls with buyers; Emails with Debtor Team	3.5
7/24/2024	Emails/calls with buyers; Emails with Debtor Team	2.0
7/25/2024	Emails/calls with buyers; Emails with Debtor Team; Call with Board	3.0
7/26/2024	Emails with buyers; Emails with Debtor Team; Board call; Internal discussion	2.5
7/27/2024	Emails with buyers; Emails with Debtor Team	0.5
7/28/2024	Emails with buyers	0.5
7/29/2024	Virtually attend court hearing; Emails with buyers; Emails with Debtor Team; Internal discussion; Call with Lender's counsel	4.0
7/30/2024	Emails with buyers; Emails with Debtor Team	2.5
7/31/2024	Emails with buyers; Emails with Debtor Team; Board call; Internal discussion	2.5
8/1/2024	Emails with buyers; Emails with Debtor Team	1.0
8/2/2024	Emails with buyers; Emails with Debtor Team; Internal discussion	1.0
8/3/2024	Emails with L/L buyer; Emails with Debtor Team	1.0
8/4/2024	Emails with L/L buyer; Emails with Debtor Team	1.0
8/5/2024	Emails with buyer for L/L assets; Call with Debtor Team	1.5
8/6/2024	Emails with buyer; Emails with Debtor Team; Internal discussion	1.5
8/7/2024	Emails with buyer; Emails with Debtor Team; Internal discussion	1.0

*Eiger BioPharmaceuticals - Case No. 24-80040 (SGL)*

*J. Scott Victor; Managing Director*

*SSG Advisors; LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
8/8/2024	Emails with buyer; Emails with Debtor Team; Call with L/L buyer	2.0
8/9/2024	Emails with buyer; Emails with Debtor Team	1.0
8/10/2024	Emails with Debtor Team	0.5
8/11/2024	Emails with Debtor Team; Internal discussion	1.0
8/12/2024	Emails with buyer; Emails with Debtor Team	1.0
8/13/2024	Emails with buyer; Emails with Debtor Team; Call with L/L buyer	1.5
8/14/2024	Emails with buyers; Emails with Debtor Team	1.0
8/15/2024	Emails with Debtor Team	1.0
8/16/2024	Emails with Debtor Team; Board call	1.5
8/17/2024	Emails with Debtor Team; Prep for L/L Sale Hearing on 8/20	1.5
8/18/2024	Review Declaration for L/L Sale Hearing; Emails with Debtor Team	2.0
8/19/2024	Emails with Debtor Team; Fly to Dallas, TX; Prep for Sale Hearing	7.0
8/20/2024	Attend court hearing - sale of L/L assets - testimony; Emails with Debtor Team; Travel Dallas to Philadelphia	12.0
8/21/2024	Emails with Debtor Team; Internal discussion	1.0
8/22/2024	Emails with Debtor Team	1.0
8/23/2024	Emails with Debtor Team; Board call; Internal discussion	2.0
8/24/2024	Emails with Debtor Team	0.5
8/25/2024	Emails with Debtor Team	0.5
8/26/2024	Emails with Debtor Team	1.0
8/27/2024	Emails with Debtor Team	1.0
8/28/2024	Emails with Debtor Team	1.0
8/29/2024	Emails with Debtor Team	1.0
8/30/2024	Weekly Board update call; Emails with Debtor Team	2.0
8/31/2024	Emails with Debtor Team	1.0
9/3/2024	Emails with Debtor Team	1.0
9/4/2024	Emails with Debtor Team	3.0
9/5/2024	Emails with buyer; Emails with Debtor Team; Virtually attend court hearing-plan confirmation	3.5
<b>Total</b>		<b>459.0</b>

*Eiger BioPharmaceuticals. - Case No. 24-80040 (SGL)*

*Teresa C. Kohl, Managing Director*

*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
4/1/2024	Weekly process update call with Debtor team; review docket; emails with Debtor team; calls/emails with buyers; buyer research; review marketing materials; internal discussion	7.0
4/2/2024	Review docket and bankruptcy filings; emails with Debtor team; calls/emails with buyers; review buyers list; review marketing materials; internal discussion	8.0
4/3/2024	Calls/emails with buyers; emails with Debtor team; review marketing materials; review docket and bankruptcy filings; attend first day hearing Webex; internal discussion	7.5
4/4/2024	Calls/emails with buyers; review marketing materials; review marketing process launch; review NDAs; emails with Debtor team; internal discussion	6.0
4/5/2024	Calls/emails with buyers; calls/emails with Debtor team; calls/emails with stakeholders; review marketing materials; review buyer outreach/marketing; internal discussion	8.0
4/6/2024	Emails with buyers; emails with Debtor team; review diligence requests; internal discussion	2.5
4/7/2024	Emails with buyers; emails with Debtor team; review diligence requests; internal discussion	2.5
4/8/2024	Calls/emails with buyers; calls/emails with Debtor team; review buyer outreach/marketing; review process update report; weekly advisor call with Debtor team and board	8.0
4/9/2024	Call with buyer and stakeholder; stakeholder follow up; calls/emails with buyers; calls/emails with Debtor team; review buyer outreach; review diligence requests; review docket; internal discussion	7.0
4/10/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence requests and status; review buyer outreach; internal discussion	6.5
4/11/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence requests and status; review buyer outreach; review process update; call with lender; internal discussion	8.0
4/12/2024	Calls/emails with buyers; calls/emails with Debtor team; weekly advisor call with Debtor team and board; auction prep and logistics review; internal discussion	7.5
4/13/2024	Emails with buyers; emails with Debtor team; review diligence requests; auction prep; internal discussion	3.5
4/14/2024	Buyer emails; emails with Debtor team; emails with stakeholder; auction prep; internal discussion	3.5
4/15/2024	Call with stakeholder and Debtor team; calls/emails with buyers; calls/emails with Debtor team; review process update; weekly advisor call with Debtor team and board; review bids; review diligence status; auction prep; internal discussion	8.0
4/16/2024	Review and qualify bids with Debtor team; calls/emails with buyers; calls/emails with Debtor team; call with lender; auction prep; internal discussion	8.5
4/17/2024	Auction prep; attend auction Zoom; calls/emails with buyers; calls/emails with Debtor team; post-auction follow up; internal discussion	9.0
4/18/2024	Calls/emails with buyers; calls/emails with Debtor team; buyer diligence call; internal discussion	4.0
4/19/2024	Board call; calls/emails with buyers; calls/emails with Debtor team; review diligence requests and status; internal discussion	6.0
4/20/2024	Emails with buyers; calls/emails with Debtor team; internal discussion	3.0
4/21/2024	Emails with buyers; calls/emails with Debtor team; internal discussion	3.0
4/22/2024	Calls/emails with buyers; calls/emails with Debtor team; weekly advisor call with Debtor team and board; auction prep and logistics review; sale hearing review; review docket; internal discussion	7.0
4/23/2024	Attend Zokinvy sale hearing Webex; calls/emails with buyers; calls/emails with Debtor team; review diligence; review buyer outreach; internal discussion	7.0
4/24/2024	Calls/emails with buyers; calls/emails with Debtor team; review marketing materials; review diligence; internal discussion	5.0
4/25/2024	Calls/emails with buyers; calls/emails with Debtor team; review marketing materials; review diligence; internal discussion	5.5
4/26/2024	Calls/emails with buyers; calls/emails with Debtor team; buyer outreach; review process update; Board call; call with lender; internal discussion	7.0
4/27/2024	Emails with buyers; emails with Debtor team	1.5
4/28/2024	Emails with buyers; emails with Debtor team	1.0
4/29/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; weekly advisor call with Debtor team and board; review buyer outreach; internal discussion	4.5
4/30/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	3.0
5/1/2024	Calls/emails with buyers; calls/emails with Debtor team; attend hearing Webex; internal discussion	2.5
5/2/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	2.0
5/3/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update report; call with lender	5.0
5/4/2024	Emails with buyers; emails with Debtor team	1.0
5/5/2024	Emails with buyers; emails with Debtor team	1.0
5/6/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; weekly advisor call with Debtor team and board; review buyer outreach; diligence review; review docket; internal discussion	7.0

*Eiger BioPharmaceuticals. - Case No. 24-80040 (SGL)**Teresa C. Kohl, Managing Director**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
5/7/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence status; attend second day hearing Webex; internal discussion	5.5
5/8/2024	Emails with buyers; buyer outreach; internal discussion	3.0
5/9/2024	Calls/emails with buyers; calls/emails with Debtor team; management meeting; review diligence; internal discussion	4.5
5/10/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; Board call; review diligence request and status; internal discussion	5.5
5/11/2024	Emails with buyers; emails with Debtor team	1.0
5/12/2024	Emails with buyers; emails with Debtor team	1.0
5/13/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; weekly advisor call with Debtor team and board; review diligence status; review buyer term sheet; internal discussion	5.5
5/14/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence status; review buyer outreach; internal discussion	3.5
5/15/2024	Emails with buyers; emails with Debtor team; review diligence status; internal discussion	3.0
5/16/2024	Emails with buyers; calls/emails with Debtor team; review buyer outreach; internal discussion	3.0
5/17/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; Board call; review diligence requests and status; internal discussion	4.5
5/18/2024	Emails with buyers	1.0
5/19/2024	Emails with buyers	1.0
5/20/2024	Calls/emails with buyers; calls/emails with Debtor team; weekly advisor call with Debtor team and board; internal discussion	4.5
5/21/2024	Calls/emails with buyers; management meeting; calls/emails with Debtor team; review draft asset purchase agreement; review diligence; review docket; internal discussion	6.5
5/22/2024	Calls/emails with buyers; management meeting; calls/emails with Debtor team; review draft asset purchase agreement; review draft term sheet; review diligence status; internal discussion	5.5
5/23/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence status; internal discussion	3.5
5/24/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; Board call; review diligence status; internal discussion	4.5
5/25/2024	Emails with buyers; emails with Debtor team	1.0
5/26/2024	Emails with buyers; emails with Debtor team	1.0
5/27/2024	Emails with buyers; emails with Debtor team	1.0
5/28/2024	Calls/emails with buyers; calls/emails with Debtor team; management meeting; internal discussion	5.5
5/29/2024	Calls/emails with buyers; calls/emails with Debtor team; attend hearing Webex; review diligence status; internal discussion	5.5
5/30/2024	Calls/emails with buyers; calls/emails with Debtor team; management meeting; review diligence status; internal discussion	4.5
5/31/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; Board call; review diligence status; internal discussion	4.5
6/1/2024	Emails with Debtor team	1.0
6/2/2024	Emails with Debtor team	1.0
6/3/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; weekly advisor call with Debtor and board; review diligence requests and status; internal discussion	5.5
6/4/2024	Calls/emails with buyers; calls/emails with Debtor team; review revised draft term sheet; internal discussion	3.5
6/5/2024	Calls/emails with buyers; calls/emails with Debtor team; review draft term sheet discussion with Debtor team; internal discussion	4.5
6/6/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence status; internal discussion	4.5
6/7/2024	Calls/emails with buyers; calls/emails with Debtor team; management meeting; review process update; Board call; review revised draft asset purchase agreement; review diligence status; internal discussion	7.5
6/8/2024	Emails with buyers; internal discussion	1.0
6/9/2024	Emails with buyers; internal discussion	1.0
6/10/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; weekly advisor call with Debtor and board; review draft asset purchase agreement; calls with Debtor team re: stalking horse proposals and proposal review; internal discussion	9.0
6/11/2024	Calls/emails with buyers; calls/emails with Debtor team; review stalking horse bids; review bid summary presentation; review diligence status; auction prep; review final stalking horse proposal; Board call to select stalking horse bidder; internal discussion	8.0
6/12/2024	Calls/emails with buyers; calls/emails with Debtor team; auction prep; internal discussion	5.5
6/13/2024	Calls/emails with Debtor team; review revised stalking horse asset purchase agreement; auction prep and logistics; internal discussion	5.5

*Eiger BioPharmaceuticals. - Case No. 24-80040 (SGL)**Teresa C. Kohl, Managing Director**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
6/14/2024	Calls/emails with buyers; calls/emails with Debtor team; Board call; auction prep and call with Debtor counsel; internal discussion	5.5
6/15/2024	Auction prep; emails with buyers; emails with Debtor team; internal discussion	2.5
6/16/2024	Auction prep; emails with buyers; emails with Debtor team; internal discussion	2.5
6/17/2024	Calls/emails with buyers; calls/emails with Debtor team; auction prep; attend auction Zoom; Board call to approve auction results; internal discussion	8.0
6/18/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence request and status; internal discussion	3.5
6/19/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence request and status; internal discussion	2.5
6/20/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence request and status; internal discussion	2.0
6/21/2024	Calls/emails with buyers; calls/emails with Debtor team; Board call; diligence review; internal discussion	4.0
6/22/2024	Calls/emails with buyers; internal discussion	1.0
6/23/2024	Calls/emails with buyers; internal discussion	1.0
6/24/2024	Calls/emails with buyers; calls/emails with Debtor team; call re: forecast review; review process update; weekly advisor call with Debtor and board; review and discuss revised term sheet; review sale declaration; internal discussion	6.5
6/25/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence status; internal discussion	3.0
6/26/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence status; attend sale hearing Webex; internal discussion	3.5
6/27/2024	Emails with buyers; emails with Debtor team; review asset valuation analysis; internal discussion	2.5
6/28/2024	Calls/emails with buyers; emails with Debtor team; Board call; review asset valuation analysis; internal discussion	3.0
6/29/2024	Emails with buyers; emails with Debtor team; review asset valuation; internal discussion	3.0
6/30/2024	Emails with buyers; emails with Debtor team; review asset valuation; internal discussion	3.0
7/1/2024	Emails with buyers; calls/emails with Debtor team; review and discuss asset valuation; call and review of draft asset purchase agreement for remaining assets; internal discussion	3.5
7/2/2024	Calls/emails with buyers; emails with Debtor team; call with Debtor advisors to discuss asset valuation; review valuation; Board call; internal discussion	4.0
7/3/2024	Calls with buyers; emails with Debtor team; review valuation; review marketing materials for remaining assets; internal discussion	3.5
7/4/2024	Emails with Debtor team; calls/emails with buyers; internal discussion	2.0
7/5/2024	Calls/emails with buyers; emails with Debtor team; review valuation analysis; review marketing materials; internal discussion	3.0
7/6/2024	Emails with buyers; internal discussion	1.0
7/7/2024	Emails with buyers; internal discussion	1.0
7/8/2024	Calls/emails with buyers; calls/emails with Debtor team; review valuation presentation; review process tracker; review revised asset purchase agreement; internal discussion	4.5
7/9/2024	Calls/emails with buyers; calls/emails with Debtor team; review diligence requests and status; review revised proposal; internal discussion	4.0
7/10/2024	Calls/emails with buyers; calls/emails with Debtor team; review revised proposal; internal discussion	4.0
7/11/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; buyer outreach; review revised proposal and buyer concerns; internal discussion	5.0
7/12/2024	Calls/emails with buyers; calls/emails with Debtor team; review process update; Board call; review proposals; review diligence; internal discussion	4.0
7/13/2024	Emails with buyers; call with buyers; internal discussion	2.0
7/14/2024	Emails with buyers; call with buyers; internal discussion	1.5
7/15/2024	Calls/emails with buyers; calls/emails with Debtor team; Board call; review proposals; internal discussion	3.5
7/16/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	2.0
7/17/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	2.0
7/18/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	2.0
7/19/2024	Calls/emails with buyers; calls/emails with Debtor team; Board call; management meeting; review diligence; internal discussion	4.0
7/20/2024	Calls/emails with buyers; emails with Debtor team; review draft asset purchase agreement and schedules; internal discussion	2.0
7/21/2024	Calls/emails with buyers; emails with Debtor team; review draft asset purchase agreement and schedules; internal discussion	3.0
7/22/2024	Calls/emails with buyers; emails with Debtor team; review draft asset purchase agreement schedules and reconciliation; internal discussion	4.0
7/23/2024	Calls/emails with buyers; emails with Debtor team; review contract assumption and list analysis; review asset purchase agreement package issues; internal discussion	4.0

*Eiger BioPharmaceuticals. - Case No. 24-80040 (SGL)*

*Teresa C. Kohl, Managing Director*

*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
7/24/2024	Calls/emails with buyers; emails with Debtor team; review contract assumption and list analysis; review issues; internal discussion	3.0
7/25/2024	Calls/emails with buyers; calls/emails with Debtor team; diligence review; Board update; internal discussion	4.0
7/26/2024	Calls/emails with buyers; calls/emails with Debtor team; diligence review; review execution version issues; Board call; internal discussion	3.5
7/27/2024	Calls/emails with buyers; emails with Debtor team; internal discussion	2.0
7/28/2024	Calls/emails with buyers; emails with Debtor team; internal discussion	2.0
7/29/2024	Calls/emails with buyers; calls/emails with Debtor team; attend disclosure court hearing Webex; diligence review; internal discussion	5.5
7/30/2024	Calls/emails with buyers; calls/emails with Debtor team; review proposals; review diligence; internal discussion	3.5
7/31/2024	Calls/emails with buyers; calls/emails with Debtor team; review proposals; review diligence; internal discussion	3.0
8/1/2024	Calls/emails with buyers; calls/emails with Debtor team; call with buyer and counsel re: deal terms; diligence review; internal discussion	3.0
8/2/2024	Calls/emails with buyers; calls/emails with Debtor team; reviewing asset purchase signing issues; internal discussion	2.0
8/3/2024	Emails with buyers; internal discussion	1.0
8/4/2024	Emails with buyers; internal discussion	1.0
8/5/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	2.0
8/6/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.5
8/7/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.5
8/8/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.5
8/9/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.5
8/10/2024	Calls/emails with Debtor team; internal discussion	1.0
8/11/2024	Calls/emails with Debtor team; internal discussion	1.0
8/12/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.0
8/13/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.0
8/14/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.0
8/15/2024	Calls/emails with buyers; calls/emails with Debtor team; internal discussion	1.0
8/16/2024	Calls/emails with buyers; calls/emails with Debtor team; Board call internal discussion	1.5
8/17/2024	Emails with buyers; emails with Debtor team; internal discussion	1.0
8/18/2024	Emails with buyers; emails with Debtor team; internal discussion	1.0
8/19/2024	Emails with buyers; emails with Debtor team; internal discussion	1.5
8/20/2024	Emails with Debtor team; attend sale hearing Webex; emails with buyers; internal discussion	2.0
8/21/2024	Emails with buyers; emails with Debtor team	1.0
8/22/2024	Emails with Debtor team	1.0
8/23/2024	Emails with Debtor team; Board call	1.5
8/24/2024	Emails with Debtor team	1.0
8/25/2024	Emails with Debtor team	1.0
8/26/2024	Emails with buyer; emails with Debtor team	1.0
8/27/2024	Emails with Debtor team	1.0
8/28/2024	Emails with Debtor team	1.0
8/29/2024	Emails with Debtor team	1.0
8/30/2024	Emails with Debtor team; Board call	1.5
8/31/2024	Emails with Debtor team	0.5
9/1/2024	Emails with Debtor team	0.5
9/2/2024	Emails with Debtor team; review docket	1.0
9/3/2024	Emails with Debtor team; review docket	1.0
9/4/2024	Emails with Debtor team; review docket	1.0
9/5/2024	Emails with Debtor team; attend Plan hearing Webex; emails with buyers; internal discussion	3.0
<b>Total</b>		<b>533.0</b>

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*  
*Craig D. Warznak, Senior Vice President*  
*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
1-Apr-24	Weekly advisor and Company update call, review BK filings, emails with professionals, buyer calls/emails, buyer research, internal discussion, data site management, review marketing materials	7.0
2-Apr-24	Review BK filings, internal discussion, emails with professionals, buyer calls/emails, review buyers list, review marketing materials	8.0
3-Apr-24	Virtually attend 1st day hearing, review BK filings, buyer calls/emails, review NDAs, review marketing materials, internal discussion, emails with professionals	7.0
4-Apr-24	Review marketing materials, launch formal marketing process, buyer calls/emails, review NDAs, data site management, emails with professionals, data site management	7.0
5-Apr-24	Buyer calls/emails, calls/emails with professionals, review NDAs, data site management, internal discussion, review marketing materials, follow-up buyer outreach/marketing	7.0
6-Apr-24	NDA review, buyer emails, emails with professionals, review due diligence requests, data site management	4.0
7-Apr-24	NDA review, buyer emails, emails with professionals, review due diligence requests, data site management	3.0
8-Apr-24	Buyer calls/emails, review NDAs, data site management, follow-up buyer outreach/marketing, emails with professionals, internal discussion, review process update report, weekly advisor and Company update call	8.0
9-Apr-24	Buyer calls/emails, review NDAs, emails with professionals, buyer outreach, review due diligence requests, data site management, emails with management	6.0
10-Apr-24	Buyer calls/emails, review NDAs, emails/calls with professionals, review due diligence requests and responses, data site management, buyer outreach, emails with management	7.0
11-Apr-24	Buyer calls/emails, emails/calls with professionals, emails with management, review due diligence requests and responses, data site management, review process update report, lender update call, buyer outreach, review NDAs	8.0
12-Apr-24	Buyer calls/emails, emails/calls with professionals, emails with management, review due diligence requests and responses, review NDAs, beging auction prep	7.0
13-Apr-24	Buyer emails, emails with professionals and management, review due diligence information and requests	4.0
14-Apr-24	Buyer emails, emails with professionals and management, review due diligence information and requests, review NDAs	4.0
15-Apr-24	Buyer calls/emails, calls/emails with professionals, review process updated report, weekly call with advisors and Company, review eTon bid, review due diligence materials and requests, auction preparation	7.0
16-Apr-24	Review eTon bid, qualify bid with Debtor team, buyer calls/emails, emails/calls with professionals, data site management, review due diligence materials and requests, review NDAs, lender update call, auction prep	9.0
17-Apr-24	Auction prep, Zokinvy auction, review NDAs, calls/emails with buyers, calls/emails with professionals and management, data site review, reivew due diligence information	9.0
18-Apr-24	Buyer calls/emails, buyer DD call, emails with management, review NDAs, review due diligence information	6.0
19-Apr-24	Eigher BOD meeting, calls/emails with professionals and management, emails with buyers, review NDAs, review due diligence requests and materials	6.0
20-Apr-24	Emails with buyers, emails with professionals	2.0
21-Apr-24	Emails with buyers, emails with professionals	2.0
22-Apr-24	Review process update report, weekly advisor and Company update call, emails/calls with buyers, review NDAs, review due diligence materials	5.0
23-Apr-24	Virtually attend Zokinvy sale hearing, emails/calls with buyers, emails with professionals, review NDAs, review due diligence	6.0
24-Apr-24	Emails with buyers, emails/calls with professionals and management, review NDAs, review updated marketing materials, review due diligence	6.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)**Craig D. Warznak, Senior Vice President**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
25-Apr-24	Emails/calls with buyers, emails/calls with professionals, emails with management, review NDAs, review updated marketing materials, review due diligence	5.0
26-Apr-24	Buyer outreach, review process update report, BOD update call, emails/calls with buyers, emails/calls with management, review NDAs, review due diligence, lender update call	7.0
27-Apr-24	Emails with buyers, emails with professionals	1.0
28-Apr-24	Emails with buyers, emails with professionals	1.0
29-Apr-24	Emails with buyers, emails with professionals, review process update report, weekly advisor and Company update call, review NDAs	4.0
30-Apr-24	Emails with buyers, emails with professionals and management, review due diligence	3.0
1-May-24	Emails with buyers, review due diligence, data site management	2.0
2-May-24	Emails with buyers, review due diligence, data site management	2.0
3-May-24	Emails with buyers, emails with professionals and management, review process update report, lender update call	5.0
4-May-24	Emails with buyers	1.0
5-May-24	Emails with buyers	1.0
6-May-24	Emails/calls with buyers, emails with professionals and management, review process update report, weekly advisor and Company update call, review due diligence, data site management, buyer due diligence calls	6.0
7-May-24	Emails with buyers, review due diligence, virtually attend court hearing	5.0
8-May-24	Emails with buyers, review due diligence, buyer outreach	3.0
9-May-24	Emails/calls with buyers, emails with management, review due diligence	4.0
10-May-24	Emails/calls with buyers, emails/calls with professionals and management, review process update report, BOD update call, review due diligence	5.0
11-May-24	Emails with buyers	1.0
12-May-24	Emails with buyers	1.0
13-May-24	Review process update report, weekly advisor and Company update call, emails with buyers, emails with management, review due diligence, review revised buyer term sheet	5.0
14-May-24	Emails/calls with buyers, emails with management, review due diligence, data site management	3.0
15-May-24	Emails with buyers, emails with management, review due diligence	3.0
16-May-24	Emails with buyers, emails with professionals and management, review due diligence, data site management	3.0
17-May-24	Review process update report, BOD update call, emails with buyers, emails with professionals and management, review due diligence	4.0
18-May-24	Emails with buyers	1.0
19-May-24	Emails with buyers	1.0
20-May-24	Review process update report, weekly advisor and Company update call, emails with buyers, emails with professionals and management, review due diligence	5.0
21-May-24	Emails/calls with buyers, emails/calls with professionals and management, review draft Amylyx APA, review due diligence	6.0
22-May-24	Emails with buyers, emails with professionals and management, review draft Spruce Bio term sheet	5.0
23-May-24	Emails with buyers, emails with management, review due diligence	3.0
24-May-24	Emails/calls with professionals and management, review process update report, BOD update call, emails with buyers, review due diligence	4.0
25-May-24	Emails with buyers, emails with professionals	1.0
26-May-24	Emails with buyers, emails with professionals	1.0
27-May-24	Emails with buyers, emails with professionals	1.0
28-May-24	Emails/calls with buyers, emails/calls with professionals and management, management DD call with buyer, review due diligence	5.0
29-May-24	Virtually attend court hearing, emails/calls with buyers, emails with management, review due diligence	5.0
30-May-24	Emails/calls with buyers, emails with management, management DD call with buyer, review due diligence	4.0



*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)**Craig D. Warznak, Senior Vice President**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
31-May-24	Review process update report, BOD update call, emails with buyers, emails with management, review due diligence	4.0
1-Jun-24	Emails with management	1.0
2-Jun-24	Emails with management	1.0
3-Jun-24	Review process update report, weekly advisor and Company update call, emails with professionals and management, emails/calls with buyers, review due diligence	5.0
4-Jun-24	Emails with buyers, emails with professionals, review revised draft buyer term sheet	3.0
5-Jun-24	Emails/calls with professionals and management, emails with buyers, review revised draft buyer term sheet with management and professionals	5.0
6-Jun-24	Emails with buyers, review due diligence, emails with management	4.0
7-Jun-24	Emails/calls with buyers, management DD call with buyer, review due diligence, review process update report, weekly BOD update call, review revised Amylyx draft APA	7.0
8-Jun-24	Emails with buyers, review due diligence, data site management	1.0
9-Jun-24	Emails with buyers, review due diligence, data site management	1.0
10-Jun-24	Review process update report, weekly advisor and Company update call, emails with buyers, emails with professionals and management, review draft Spruce Bio APA, call with professionals to discuss Avexitide stalking horse proposals, call with professionals and management to review proposals	8.0
11-Jun-24	Review stalking horse bids, review bid comparison presentation, review due diligence, emails with buyers, emails with professionals and management, auction preparation, review final stalking horse proposals, BOD call to select Avexitide stalking horse	7.0
12-Jun-24	Auction prep, call with counsel to discuss auction, emails/calls with buyers, emails with professionals and management	5.0
13-Jun-24	Auction prep, review revised stalking horse APA, emails with professionals and management, data site management	5.0
14-Jun-24	Auction prep, weekly BOD update call, call with counsel regarding auction, emails/calls with buyers, emails with professionals and management	5.0
15-Jun-24	Auction prep, emails with buyers, emails with professionals	2.0
16-Jun-24	Auction prep, emails with buyers, emails with professionals	2.0
17-Jun-24	Auction prep, emails/calls with professionals and management, emails with buyers, Avexitide auction, BOD call to approve winning bid	7.0
18-Jun-24	Emails with professionals and management, emails with buyers	2.0
19-Jun-24	Emails with buyers, emails with professionals and management	1.0
20-Jun-24	Emails with buyers, emails with professionals and management	1.0
21-Jun-24	Emails with buyers, emails with professionals and management, weekly BOD update call	3.0
24-Jun-24	Emails with professionals and management, review weekly process update report, weekly advisor and Company update call, review and discuss revised terms sheet, call with professionals to discuss asset sale proceeds, review declaration in support of Avexitide sale	5.0
25-Jun-24	Travel, sale hearing prep with counsel, emails with professionals and management	5.0
26-Jun-24	Hearing prep, attend Avexitide sale hearing, emails with professionals and management, travel	5.0
27-Jun-24	Emails with professionals, review asset valuation analysis	3.0
28-Jun-24	Weekly BOD update call, emails with professionals, call with management regarding asset valuation analysis, review asset valuation	5.0
29-Jun-24	Review valuation	3.0
30-Jun-24	Review valuation	3.0
1-Jul-24	Emails with professionals and management, call with management regarding valuation, review valuation, call with buyer regarding draft APA	5.0
2-Jul-24	Emails/calls with professionals, BOD call to discuss asset valuation, review valuation, emails/calls with buyers	6.0
3-Jul-24	Review valuation, review marketing materials for select assets	4.0
4-Jul-24	Emails with management	1.0
5-Jul-24	Emails with professionals, review asset valuation analysis	2.0
8-Jul-24	Emails/calls with buyers, emails with management, data site management	3.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*  
*Craig D. Warznak, Senior Vice President*  
*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
9-Jul-24	Emails/calls with buyers, review due diligence, data site management, emails with professionals	3.0
10-Jul-24	Emails/calls with buyers, review due diligence, data site management, emails with professionals	3.0
11-Jul-24	Emails with buyers, emails with professionals and management, review process update report, buyer outreach	4.0
12-Jul-24	Review process update report, weekly BOD update call, emails with buyers, emails with professionals and management, review due diligence, data site management	3.0
15-Jul-24	Emails with buyers, emails with professionals and management, BOD update call	3.0
16-Jul-24	Emails with buyers, emails with professionals and management	2.0
17-Jul-24	Emails with buyers, emails with professionals and management	2.0
18-Jul-24	Emails with buyers, emails with professionals and management	2.0
19-Jul-24	Emails/calls with buyers, weekly BOD update call, buyer DD call with management	3.0
20-Jul-24	Emails with buyers, data site management	1.0
21-Jul-24	Emails with buyers	1.0
22-Jul-24	Emails with buyers, emails with professionals and management, due diligence review	2.0
23-Jul-24	Emails/calls with buyers, emails with professionals and management, due diligence review, data site management	3.0
24-Jul-24	Emails/calls with buyers, emails with professionals and management, due diligence review, data site management	3.0
25-Jul-24	Emails/calls with buyers, emails with professionals and management, due diligence review, data site management	3.0
26-Jul-24	Emails with buyers, emails with management	2.0
27-Jul-24	Emails with buyers, emails with management, data site management	2.0
28-Jul-24	Emails with buyers	1.0
29-Jul-24	Virtually attend court hearing, emails with buyers, emails with professionals and management, due diligence review	4.0
30-Jul-24	Emails with buyers, emails with professionals and management, due diligence review	2.0
31-Jul-24	Emails with buyers, emails with professionals and management, due diligence review	2.0
1-Aug-24	Emails with buyers, emails with professionals and management, due diligence review	1.0
2-Aug-24	Emails with buyers, emails with professionals and management, due diligence review	1.0
5-Aug-24	Emails with buyers	1.0
6-Aug-24	Emails with buyers, emails with professionals and management	1.0
7-Aug-24	Emails with buyers, emails with professionals and management	1.0
8-Aug-24	Emails with buyers, emails with professionals and management	1.0
9-Aug-24	Emails with buyers, emails with professionals and management	1.0
10-Aug-24	Emails with professionals, data site management	1.0
11-Aug-24	Emails with professionals, data site management	1.0
12-Aug-24	Emails with buyers, data site management	1.0
13-Aug-24	Emails with buyers, emails with professionals and management	1.0
14-Aug-24	Emails with buyers	1.0
15-Aug-24	Emails with professionals	1.0
19-Aug-24	Emails with professionals	1.0
20-Aug-24	Virtually attend court hearing, emails with professionals	1.0
21-Aug-24	Emails with buyers, emails with professionals	1.0
22-Aug-24	Emails with professionals	1.0
26-Aug-24	Emails with professionals	1.0
27-Aug-24	Emails with professionals	1.0
28-Aug-24	Emails with professionals	1.0
29-Aug-24	Emails with professionals	1.0
30-Aug-24	Weekly BOD update call	1.0
31-Aug-24	Emails with professionals and management	1.0
3-Sep-24	Emails with professionals	1.0
4-Sep-24	Emails with professionals	1.0
5-Sep-24	Emails with buyers, emails with professionals and management, virtually attend court hearing	3.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*

*Craig D. Warznak, Senior Vice President*

*SSG Advisors, LLC*

Date	Task	Hours
<b>Total</b>		<b>471.0</b>

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*

*Alexander D. Lamm, Senior Associate*

*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
1-Apr-24	Weekly advisors and Company update call; Reviewed first day declaration and BK filings on the docket; Marketing material prep; Internal emails; Populated buyer data room; Emails with Counsel; Emails with Company; Reviewed internal Company documents; Internal discussions related to bifurcated sale process; Docket tracking; Emails with buyers; Reviewed Company's internal share files re: buyer data room setup; Buyer research; Buyer outreach prep;	8.0
2-Apr-24	Emails with Company re: stalking horse agreements; Calls with buyers; Marketing material prep Re; Teaser; Internal meetings re: marketing strategy; Emails with Buyers; NDA review; Buyer tracking; Docket tracking; Reviewed internal Company documents; Data room management; process tracking; Reviewed stalking horse asset purchase agreement; Diligence request management;	8.0
3-Apr-24	First day hearing; Emails with Counsel; Calls with multiple potential Zokinvy and other asset buyers re: timeline and process; NDA review; Process tracking; Emails with management re: diligence information; Data room management; Marketing material development; Docket tracking; Diligence request management; Buyer research; Docket tracking;	8.0
4-Apr-24	Calls with buyers; Emails with buyers; Docket tracking; Data room management; Internal meetings on sale process for Zokinvy and other assets; Marketing material updates; NDA review; NDA management; Outreach strategy review; Emails with Counsel; Docket tracking;	8.0
5-Apr-24	Emails with Company, Emails with Counsel re: diligence requests; Calls with buyers; Emails with buyers; Data room management; Reviewed internal Company documents; Emails with Financial Advisors re: diligence requests; NDA Review; Process tracking; Call with SSG and PRF; Diligence request management; Reviewed APA exhibits re: sublicense, side letter and novation agreement;	8.0
6-Apr-24	Reviewed Company prepared diligence requests for buyers re: Zokinvy Sales Reports; Emails with buyers; Emails with Company; Data room management;	6.0
7-Apr-24	Emails with buyers; Emails with Company; Data room management; Diligence request management;	4.0
8-Apr-24	Buyer and management diligence call; Weekly advisors and Company update call; NDA review; Data room management; Emails with buyers; Emails with Company; Process update review; Diligence request management; Reviewed Company prepared diligence requests for buyers re: Zokinvy Supply Chain; Docket tracking; Process tracking; Reviewed 13 week cash flow;	8.0
9-Apr-24	Buyer call with PRF and SSG; Buyer and management diligence call; Emails with buyers re: Zokinvy diligence; Follow ups with active buyers re: Zokinvy assets; NDA Review; Emails with Company re: Zokinvy patient status; Emails with Counsel; Data room management; Process tracking;	8.0
10-Apr-24	Emails with buyers; Calls with Buyers; Emails with Counsel; Diligence request management re: Zokinvy; Call with Company, Counsel and Financial Advisor re: Internal updates; Emails with PRF re: bidder introductory call coordination; Data room management; NDA review;	8.0
11-Apr-24	Reviewed Company prepared diligence Re: Zokinvy Inventory; Emails with buyers; Calls with Buyers; Data room management; Emails with Counsel; Emails with Company; Diligence request management; Reviewed internal Company documents; Update call with Company, Counsel and Financial Advisor; Cash Collateral call with Lender; NDA review; Docket tracking;	8.0
12-Apr-24	Emails with Buyers; Calls with Buyers; Data room management; Reviewed Company prepared diligence requests; Emails with Counsel; Buyer call with PRF and SSG; Buyer and management diligence call re: Avexitide; Calls with other asset buyers re: process and timing; Call with Counsel re: Auction logistics; Internal Auction prep; Diligence request management; Docket tracking; Emails with buyers re: bidding procedures; Follow ups with Zokinvy buyers re: bid deadline;	8.0
13-Apr-24	Emails with buyers re: bidding procedures; Diligence request management; Emails with Counsel; Emails to potential bidders with PRF executive statement as consultation party; Emails with Company re: outstanding diligence requests;	7.0
14-Apr-24	Emails with buyers re: outstanding diligence requests; Emails with Counsel; Auction prep;	7.0
15-Apr-24	Auction prep; Call with SSG and PRF re: Sale process update; Weekly advisors and Company update call; Emails with buyers; Calls with Buyers; Emails with Company; Emails with Counsel; Data room management; Process tracking; Diligence request tracking; Reviewed bid package;	8.0
16-Apr-24	Auction prep; Call with advisors and Company to discuss qualified bid; Call with lender re: sale process for Zokinvy and other assets and auction; Call with buyers re: non-Zokinvy assets; Calls with Buyers; Emails with Company; Emails with Counsel; Data room management; Process tracking; Diligence request tracking; Emails re: auction protocol; Auction prep and management;	9.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)**Alexander D. Lamm, Senior Associate**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
17-Apr-24	Auction prep; Auction bid tracking analysis; Auction protocol tracking; Conduct auction for Zokinvy Assets; Emails with buyers; Calls with Buyers;	8.0
18-Apr-24	Emails with Buyers; NDA Review; Emails with Counsel re: winning bid notice; Process update review; Diligence call with buyer re: Avexitide; Internal meeting re: other asset sale process;	7.0
19-Apr-24	Emails with Counsel re: NDAs; Email follow ups to other asset buyers; Eiger board call; Emails with Company; Emails with Avexitide buyer re: IP diligence questions; NDA review; Data room management; Docket tracking;	7.0
20-Apr-24	Emails with Company; Emails with Counsel;	1.0
21-Apr-24	Emails with Company; Emails with Counsel;	1.0
22-Apr-24	NDA review; Process update review; Data room management; Docket tracking; Emails with buyers; Weekly advisors and Company update call; Calls with buyers; Diligence request management re: Avexitide;	7.0
23-Apr-24	Emails with Counsel re: court reporter; Emails with Buyers re: Avexitide; Diligence request management re: Avexitide; Zokinvy sale hearing; Emails with Company re: Diligence; Data room management; NDA review;	7.0
24-Apr-24	Emails with buyers; Data room management; Emails with Company; Diligence request management re: Lonafarnib HDV and Lambda; Emails with Financial Advisor;	7.0
25-Apr-24	Emails with Counsel; Calls with buyer re: Lonafarnib HDV and Lambda; Emails with Company; NDA review; Data room management; Emails with buyers; Reviewed diligence information from Company;	5.0
26-Apr-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
27-Apr-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
29-Apr-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
30-Apr-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
1-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
2-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
3-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
6-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
7-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
8-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
9-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
10-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
13-May-24	Emails with buyers re: outstanding diligence requests; Emails with Counsel; Data room management; Weekly advisors and Company update call; Process update review; Lonafarnib HDV Form APA review;	6.0
14-May-24	Diligence call re: Avexitide; Data Room management; emails with counsel; Emails with Buyers; Docket Tracking; Emails with Company re: Lonafarnib HDV program; Diligence request management; Emails with Counsel;	6.0
15-May-24	Emails with Company re: diligence requests; Emails with buyers; Reviewed diligence information from Company; Diligence request tracking; Data room management;	4.0
16-May-24	Diligence call re: Avexitide manufacturing; Emails with Company; Emails with buyers; Reviewed diligence information from Company; Diligence request tracking; Data room management;	4.0
17-May-24	Board call; Process summary; Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation;	4.0
20-May-24	Emails with buyers, internal team, and other advisors;	4.0
21-May-24	Emails with buyers, internal team, and other advisors; Call with Company and Advisors; Diligence supplementation; Call with potential buyer	4.0
22-May-24	Emails with buyers, internal team, and other advisors;	2.0
23-May-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	2.0
24-May-24	Board call; Emails with buyers, internal team, and other advisors;	3.0
25-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors; Process tracking; VDR management; Diligence request tracking;	3.0
27-May-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
28-May-24	Management call with potential Avexitide buyer; IP discussion with potential Avexitide buyer; Emails with buyers, Emails with Counsel, internal team, and other advisors;	3.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)**Alexander D. Lamm, Senior Associate**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
29-May-24	Hearing; Emails with buyers, internal team, and other advisors; IP Counsel meeting with potential buyer;	4.0
30-May-24	Management call with potential buyer; Emails with buyers, Emails with Counsel, internal team, and other advisors;	3.0
31-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation;	3.0
2-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
3-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
4-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
5-Jun-24	Call with buyer re: Lonafarnib; Emails with buyers, Emails with Counsel, internal team, and other advisors; Diligence supplementation;	2.0
6-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	2.0
7-Jun-24	Calls with potential Avexitide buyer: Emails with buyers, Emails with Counsel, internal team, and other advisors; Diligence supplementation; Board call; Process summary;	4.0
8-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	1.0
9-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	1.0
10-Jun-24	Emails with buyers, internal team, and other advisors; Process summary; Call(s) with Company and Advisors; Diligence supplementation; Offer comparison	4.0
11-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation; Board call; Offer analysis	5.0
12-Jun-24	Emails with buyers, internal team, and other advisors; Discussion with Counsel on Auction; Discussion with interested party; Auction prep;	4.0
13-Jun-24	Emails with buyers, internal team, and other advisors; Auction prep	2.0
14-Jun-24	Avexitide Auction Prep; Emails with Company re: confirming the auction date and time; Emails with bidders re: auction participation Excel form; Emails with bidders re: auction protocols and procedures; Internal tracking re: updating master auction attendee list once auction participant forms from each bidder are returned to SSG; Internal alignment re: confirming opening bid and procedures for bidding increments; Internal preparation re: live auction tracking sheet; Setup conference room for auction purposes	8.0
16-Jun-24	Auction prep; Internal emails;	2.0
17-Jun-24	Conducted Avexitide Auction; Emails with court reporter re: sending the final auction participation list; Emails with court reporter re: sending the auction keywords list;	6.0
18-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
19-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
20-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
21-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
24-Jun-24	Emails with buyers, Emails with Counsel, internal team, and other advisors;	1.0
25-Jun-24	Emails with Counsel, internal team, and other advisors;	1.0
26-Jun-24	Hearing; Emails with Counsel, internal team, and other advisors;	1.0
27-Jun-24	Emails with Counsel, internal team, and other advisors; Internal emails re: valuation;	2.0
28-Jun-24	Emails with buyers, internal team, and other advisors; Advisor call; Board call; Valuation work; Call with Company on valuation	3.0
29-Jun-24	Valuation work;	1.0
30-Jun-24	Valuation work;	1.0
1-Jul-24	Emails with buyers, internal team, and other advisors; Call with Company to discuss valuation; Valuation research; Lambda / Lonafarnib bid submission discussion with Counsel and interested party	4.0
2-Jul-24	Emails with buyers, internal team, and other advisors; Valuation research; Lambda / Lonafarnib bid submission discussion with Counsel and interested party	2.0
3-Jul-24	Virology buyer research; Emails with buyers, internal team, and other advisors; Buyer diligence	5.0
5-Jul-24	Emails with Counsel, internal team, and other advisors; Internal emails re: valuation;	2.0
8-Jul-24	Emails with buyers, internal team, and other advisors; Asset remarket; Process tracking;	6.0
9-Jul-24	Emails with buyers, internal team, and other advisors; Process tracking; Diligence supplementation; VDR management; Calls with interested parties; POC research	5.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)**Alexander D. Lamm, Senior Associate**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
10-Jul-24	Emails with buyers, internal team, and other advisors; Diligence supplementation; VDR management; NDA management	3.0
11-Jul-24	Emails with buyers, internal team, and other advisors; Process summary updates remarket;	3.0
12-Jul-24	Emails with buyers, internal team, and other advisors; Emails re: Lambda; Reviewed the notice of bid deadlines for Lonafarnib and Lambda;	3.0
15-Jul-24	Emails with buyers, Counsel, internal team, and other advisors; Circulated revised notice of deadlines; VDR management; Board call; Sale process call;	4.0
16-Jul-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
17-Jul-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
18-Jul-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
19-Jul-24	Emails with buyers, Counsel, internal team, and other advisors; Lambda CMC call;	3.0
20-Jul-24	VDR management; Emails with Company;	1.0
21-Jul-24	Emails with buyers re: contracts; Data room management;	2.0
22-Jul-24	Emails with buyers, Counsel, internal team, and other advisors; Data room management; Contract identification review;	3.0
23-Jul-24	Call with buyer re: Lambda; Emails with buyers, Emails with Counsel, internal team, and other advisors; Diligence supplementation; Diligence request management;	4.0
24-Jul-24	Call with buyer re: Lambda; Emails with buyers, Counsel, internal team, and other advisors;	3.0
25-Jul-24	Emails with buyers, Counsel, internal team, and other advisors; Data room management; Diligence management re: Lambda;	4.0
26-Jul-24	Emails with Company re: Lambda diligence;	3.0
27-Jul-24	Emails with Company re: Lambda diligence; Data room management;	3.0
28-Jul-24	Emails with buyers;	1.0
29-Jul-24	Emails with buyers, Counsel, internal team, and other advisors; Data room management;	2.0
30-Jul-24	Emails with buyers, Counsel, internal team, and other advisors; Data room management;	2.0
31-Jul-24	Emails with buyers, Counsel, internal team, and other advisors; Data room management;	2.0
1-Aug-24	Emails with buyers, Counsel, internal team, and other advisors; Data room management;	1.0
2-Aug-24	Emails with buyers, Counsel, internal team, and other advisors; Data room management;	1.0
5-Aug-24	Emails with Counsel; Reviewed declaration for the motion in support of the Lonafarnib/Lambda sale transactions;	3.0
6-Aug-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
7-Aug-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
8-Aug-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
9-Aug-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
10-Aug-24	Contract identification review; Data Room Management; Emails with Counsel;	3.0
11-Aug-24	Contract identification review; Data Room Management; Emails with Counsel;	3.0
12-Aug-24	Data room management; Emails with buyer;	1.0
13-Aug-24	Contract identification review; Data Room Management; Emails with Counsel;	1.0
14-Aug-24	Emails with buyers, Counsel, internal team, and other advisors;	1.0
15-Aug-24	Emails with Counsel, internal team, and other advisors;	1.0
20-Aug-24	Hearing; Emails with Counsel, internal team, and other advisors;	2.0
21-Aug-24	Contract identification review; Data Room Management; Emails with Counsel;	1.0
22-Aug-24	Emails with Counsel, internal team, and other advisors; Contract identification review; Data Room Management; Emails with Counsel;	3.0
26-Aug-24	Emails with buyer Counsel re: contracts; Contract identification review; Data Room Management; Emails with Counsel; Board call;	3.0
27-Aug-24	Emails with Counsel, internal team, and other advisors;	1.0
28-Aug-24	VDR management	1.0
29-Aug-24	VDR management	1.0
30-Aug-24	Board Call	1.0
31-Aug-24	Emails with Counsel, internal team, and other advisors;	
2-Sep-24	VDR Management	1.0
3-Sep-24	Emails with advisors	1.0
4-Sep-24	Emails with advisors	1.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*

*Alexander D. Lamm, Senior Associate*

*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
5-Sep-24	Emails with Company and Counsel re: Transfer Tax Mechanics; Hearing;	3.0
<b>Total</b>		<b>410.0</b>



*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*

*Nicholas A. Vernacchio, Senior Analyst*

*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
1-Apr-24	Work on CIM, buyers list, and VDR; Emails with buyers, internal team, and other advisors; Call with Management	7.0
2-Apr-24	Work on CIM, buyers list, and VDR; Process tracking; Emails with buyers, internal team, and other advisors; Call with potential buyer	6.0
3-Apr-24	Work on CIM, buyers list, and VDR; Process tracking; Emails with buyers, internal team, and other advisors; Calls with potential buyers; First Day Hearing	8.0
4-Apr-24	Work on VDR and CIM; NDA review; Process tracking; Emails with buyers, internal team, and other advisors; Calls with potential buyers; Market outreach	6.0
5-Apr-24	NDA review; Process tracking; Emails with buyers, internal team, and other advisors; Call with potential buyer; Follow up outreach	7.0
6-Apr-24	Emails with buyers, internal team, and other advisors	3.0
7-Apr-24	Emails with buyers, internal team, and other advisors	3.0
8-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; Call with potential buyer; Diligence supplementation; VDR management; Process summary work; buyer follow up	6.0
9-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; Call with potential buyer; Diligence supplementation; VDR management; Process summary work; Buyer follow up; Work on marketing materials	7.0
10-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking, Diligence supplementation; VDR management; Advisors call	7.0
11-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking, Diligence supplementation; VDR management; Calls with advisors and lender; Call with potential buyer	8.0
12-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking, Diligence supplementation; VDR management; Calls with potential buyers; Board call	7.0
13-Apr-24	Emails with buyers, internal team, and other advisors	2.0
14-Apr-24	Emails with buyers, internal team, and other advisors	3.0
15-Apr-24	Emails with buyers, internal team, and other advisors; Advisors call	3.0
16-Apr-24	Emails with buyers, internal team, and other advisors; Advisors call; Call with potential buyer; Auction prep; Offer comparison; Process summary work	7.0
17-Apr-24	Emails with buyers, internal team, and other advisors; Auction prep; Zokinvy auction	5.0
18-Apr-24	Emails with buyers, internal team, and other advisors; Management call with potential buyer; Process tracking	4.0
19-Apr-24	Emails with buyers, internal team, and other advisors; Call with Company; Process tracking; Diligence supplementation	5.0
20-Apr-24	Emails with buyers, internal team, and other advisors	3.0
21-Apr-24	Emails with buyers, internal team, and other advisors	2.0
22-Apr-24	Emails with buyers, internal team, and other advisors; Call with Company and advisors; Process tracking; Diligence supplementation; Board call; Call with potential buyer	4.0
23-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; Zokinvy Sale Hearing	4.0
24-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation	3.0
25-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation	2.0
26-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; Board call; Management call with potential buyer; Process summary; 2nd mass buyer outreach; VDR management; Diligence supplementation; Call with lender	7.0
28-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking	2.0
29-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; Call with the Company	4.0
30-Apr-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management	2.0
1-May-24	Emails with buyers, internal team, and other advisors; Process tracking; Hearing; VDR management; Diligence supplementation	2.0
2-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation	4.0
3-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation	2.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)**Nicholas A. Vernacchio, Senior Analyst**SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
5-May-24	Emails with buyers, internal team, and other advisors	1.0
6-May-24	Emails with buyers, internal team, and other advisors; Process tracking; Process Summary; Management call with potential buyer	3.0
7-May-24	Emails with buyers, internal team, and other advisors; Process tracking	2.0
8-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; 3rd mass buyer outreach	4.0
9-May-24	Emails with buyers, internal team, and other advisors; Process tracking; Diligence supplementation; Management call with potential buyer	3.0
10-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; Management call with potential buyer	6.0
12-May-24	Emails with buyers, internal team, and other advisors	2.0
13-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation	2.0
14-May-24	Emails with buyers, internal team, and other advisors; Process tracking; Diligence supplementation; Management call with potential buyer	3.0
15-May-24	Emails with buyers, internal team, and other advisors; Process tracking; Diligence supplementation	2.0
16-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Management call with potential buyer	3.0
17-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; Board call; Process summary	3.0
20-May-24	Emails with buyers, internal team, and other advisors; Process tracking; Process summary; Call with Company and Advisors; Diligence supplementation; Call scheduling	4.0
21-May-24	Emails with buyers, internal team, and other advisors; Process tracking; Process summary; Call with Company and Advisors; Diligence supplementation; Call with potential buyer	5.0
22-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; Call scheduling	4.0
23-May-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	3.0
24-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; Board call; Process summary	3.0
25-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation	3.0
27-May-24	Emails with buyers, internal team, and other advisors	1.0
28-May-24	Emails with buyers, internal team, and other advisors; Management meeting	2.0
29-May-24	Emails with buyers, internal team, and other advisors; IP Counsel meeting with potential buyer; Hearing; Diligence supplementation	5.0
30-May-24	Emails with buyers, internal team, and other advisors; Management call with potential buyer; Process tracking; Diligence supplementation	4.0
31-May-24	Emails with buyers, internal team, and other advisors; Process tracking; VDR management; Diligence supplementation; Board call; Process summary	3.0
2-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	3.0
3-Jun-24	Emails with buyers, internal team, and other advisors; Process summary; Call with Company and Advisors; Diligence supplementation	5.0
4-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	2.0
5-Jun-24	Emails with buyers, internal team, and other advisors; Process tracking	1.0
6-Jun-24	Emails with buyers, internal team, and other advisors; Process tracking; Diligence supplementation	2.0
7-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation; Board call; Process summary; Management call with interested party	5.0
8-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	2.0
9-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	2.0
10-Jun-24	Emails with buyers, internal team, and other advisors; Process summary; Call(s) with Company and Advisors; Diligence supplementation; Offer comparison	4.0
11-Jun-24	Emails with buyers, internal team, and other advisors; Diligence supplementation; Board call; Offer analysis	7.0
12-Jun-24	Emails with buyers, internal team, and other advisors; Discussion with Counsel on Auction; Discussion with interested party; Auction prep	6.0
13-Jun-24	Emails with buyers, internal team, and other advisors; Auction prep	4.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*

*Nicholas A. Vernacchio, Senior Analyst*

*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
14-Jun-24	Emails with buyers, internal team, and other advisors; Call with Company and advisors; Call to discuss auction; Auction prep	5.0
16-Jun-24	Emails with buyers, internal team, and other advisors; Auction prep	3.0
17-Jun-24	Emails with buyers, internal team, and other advisors; Auction prep; Call with UCC and Company advisors; Avexitide Auction, Call with Transaction Committee	7.0
18-Jun-24	Emails with buyers, internal team, and other advisors	2.0
19-Jun-24	Emails with buyers, internal team, and other advisors; Offer review	2.0
21-Jun-24	Emails with buyers, internal team, and other advisors; Board call; Create marketing materials for Remaning Assets	3.0
24-Jun-24	Emails with buyers, internal team, and other advisors; Call with UCC and Company advisors; Call with Compant FA to discuss forecast	2.0
25-Jun-24	Emails with buyers, internal team, and other advisors	1.0
26-Jun-24	Emails with buyers, internal team, and other advisors; Valuation work; Hearing	5.0
27-Jun-24	Emails with buyers, internal team, and other advisors; Valuation work	3.0
28-Jun-24	Emails with buyers, internal team, and other advisors; Advisor call; Board call; Valuation work; Call with Company on valuation	5.0
29-Jun-24	Emails with buyers, internal team, and other advisors; Valuation work	3.0
30-Jun-24	Valuation work	2.0
1-Jul-24	Emails with buyers, internal team, and other advisors; Valuation work; VDR management; Call with Company to discuss valuation; Valuation research; Lambda / Lonafarnib bid submission discussion with Counsel and interested party	8.0
2-Jul-24	Emails with buyers, internal team, and other advisors; Valuation work; Advisor calls; Transaction committee meeting; Call with interested party	4.0
3-Jul-24	Emails with buyers, internal team, and other advisors; Buyer diligence	1.0
5-Jul-24	Emails with buyers, internal team, and other advisors	1.0
8-Jul-24	Emails with buyers, internal team, and other advisors; Asset remarket; Process tracking; Valuation update; Call with interested party; Diligence supplementation; VDR management	5.0
9-Jul-24	Emails with buyers, internal team, and other advisors; Process tracking; Diligence supplementation; VDR management; Calls with interested parties; POC research	5.0
10-Jul-24	Emails with buyers, internal team, and other advisors; Diligence supplementation; VDR management; NDA management	4.0
11-Jul-24	Emails with buyers, internal team, and other advisors; Diligence supplementation	2.0
12-Jul-24	Emails with buyers, internal team, and other advisors; Board call; Call with interested party	2.0
15-Jul-24	Emails with buyers, internal team, and other advisors; Board call; Buyer outreach; VDR management	2.0
16-Jul-24	Emails with buyers, internal team, and other advisors	1.0
17-Jul-24	Emails with buyers, internal team, and other advisors; Update call with debtor professionals, creditors and creditor professionals	1.0
18-Jul-24	Emails with buyers, internal team, and other advisors	1.0
19-Jul-24	Emails with buyers, internal team, and other advisors; VDR management; Call with interested party; Diligence supplementation	2.0
22-Jul-24	Emails with buyers, internal team, and other advisors; VDR management; Diligence supplementation; Call with Company and Advisors	1.0
23-Jul-24	Emails with buyers, internal team, and other advisors; Call with interested party; Diligence supplementation	4.0
24-Jul-24	Emails with buyers, internal team, and other advisors; Diligence supplementation; Management call with interested party	2.0
25-Jul-24	Emails with buyers, internal team, and other advisors; Board call; Diligence supplementation; Management call with interested party	4.0
26-Jul-24	Emails with buyers, internal team, and other advisors; Diligence supplementation; Hearing	1.0
29-Jul-24	Emails with buyers, internal team, and other advisors	1.0
30-Jul-24	Emails with buyers, internal team, and other advisors	1.0
31-Jul-24	Emails with buyers, internal team, and other advisors; Board Call	2.0
1-Aug-24	Emails with buyers, internal team, and other advisors	1.0
2-Aug-24	Emails with buyers, internal team, and other advisors; Update call with debtor counsel and secured lender counsel; VDR management	3.0
5-Aug-24	Emails with buyers, internal team, and other advisors; Board Call	1.0

*Eiger BioPharmaceuticals, Inc., Case No. 24-80040 (SGL)*

*Nicholas A. Vernacchio, Senior Analyst*

*SSG Advisors, LLC*

<b>Date</b>	<b>Task</b>	<b>Hours</b>
7-Aug-24	Emails with buyers, internal team, and other advisors	1.0
8-Aug-24	Emails with buyers, internal team, and other advisors; Update call with debtor counsel and secured lender counsel	1.0
9-Aug-24	Emails with buyers, internal team, and other advisors	1.0
10-Aug-24	VDR management; Diligence supplementation	1.0
11-Aug-24	VDR management; Diligence supplementation	1.0
12-Aug-24	Emails with buyers, internal team, and other advisors; Board Call	1.0
13-Aug-24	VDR management; Diligence supplementation	1.0
16-Aug-24	Board Call	1.0
19-Aug-24	Board Call	1.0
21-Aug-24	Emails with buyers, internal team, and other advisors; VDR management	1.0
22-Aug-24	Emails with buyers, internal team, and other advisors; VDR management	1.0
23-Aug-24	Board Call	1.0
26-Aug-24	Board Call; VDR management	2.0
28-Aug-24	VDR management	1.0
29-Aug-24	VDR management	1.0
30-Aug-24	Board Call	1.0
5-Sep-24	Emails internal team, and other advisors	1.0
<b>Total</b>		<b>380.0</b>

**EXHIBIT E**  
**Proposed Order**

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, INC., *et al.*<sup>1</sup>

Debtors.

Chapter 11

Case No. 24-80040 (SGJ)

(Jointly Administered)

**ORDER APPROVING FIRST AND FINAL APPLICATION OF SSG ADVISORS, LLC,  
INVESTMENT BANKERS FOR THE DEBTORS, FOR ALLOWANCE OF  
COMPENSATION AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD  
APRIL 1, 2024 THROUGH AND INCLUDING SEPTEMBER 5, 2024**

Upon consideration of the *First and Final Application of SSG Advisors, LLC, Investment Banker to the Debtors, for Allowance of Compensation and Reimbursement of Expenses for the Period April 1, 2024 Through and Including September 5, 2024* (the “Fee Application”)<sup>2</sup> for entry of an order allowing, on a final basis, compensation for professional services performed by SSG as investment banker to the Debtors for the period from April 1, 2024 through September 5, 2024 (the “Application Period”); and the Court, having reviewed the Fee Application, and having found that the Court has jurisdiction over this matter pursuant to 28 U.S.C. § 1334, this is a core matter pursuant to 28 U.S.C. § 157(b)(2), notice of the Fee Application was sufficient under the circumstances and that no further notice need be given, and the legal and factual bases set forth in the Fee Application establish just cause for the relief granted; and after due deliberation and sufficient cause appearing therefor,

---

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Avenue, Dallas, Texas 75201.

<sup>2</sup> Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Fee Application.

**IT IS HEREBY FOUND AND DETERMINED THAT:**

- 1) The Fee Application is hereby approved.
- 2) The fees of SSG in the total amount of \$2,727,387.99 incurred as investment banker to the Debtor are hereby allowed and payment is authorized on a final basis as compensation and reimbursement for professional services rendered during the Application Period.

**### END OF ORDER ###**

Submitted by:

**SIDLEY AUSTIN LLP**

Thomas R. Califano (TX Bar No. 24122825)  
2021 McKinney Avenue, Suite 2000  
Dallas, Texas 75201  
Telephone: (214) 981-3300  
Facsimile: (214) 981-3400  
Email: tom.califano@sidley.com

*and*

William E. Curtin (admitted pro hac vice)  
Anne G. Wallice (admitted pro hac vice)  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: wcurtin@sidley.com  
anne.wallice@sidley.com

*Attorneys to the Debtors and  
Debtors in Possession*